<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004052" GROUP_ID="DEPRESSN" ID="984799072210034138" MERGED_FROM="" MODIFIED="2015-06-19 12:09:46 +0100" MODIFIED_BY="Jessica Sharp" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Old title: REFS TIDIED AMAP - Valproate for acute mood episodes in bipolar disorder&lt;/p&gt;" NOTES_MODIFIED="2015-06-19 12:06:31 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="062" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2015-06-19 12:09:46 +0100" MODIFIED_BY="Jessica Sharp">
<TITLE>Valproate for acute mood episodes in bipolar disorder</TITLE>
<CONTACT MODIFIED="2015-06-19 12:09:46 +0100" MODIFIED_BY="Jessica Sharp"><PERSON ID="5A7199CD82E26AA2000F11BCA4F6544D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Keith</FIRST_NAME><LAST_NAME>Reid</LAST_NAME><POSITION>Consultant forensic psychiatrist</POSITION><EMAIL_1>Keithreid@nhs.net</EMAIL_1><ADDRESS><DEPARTMENT>Bamburgh Clinic</DEPARTMENT><ORGANISATION>Northumberland Tyne and Wear NHS Foundation Trust</ORGANISATION><ADDRESS_1>Jubilee Road</ADDRESS_1><CITY>Newcastle</CITY><ZIP>NE3 3XT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 (0) 191 223 2454</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-06-19 12:09:46 +0100" MODIFIED_BY="Jessica Sharp"><PERSON ID="13181" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Karine</FIRST_NAME><LAST_NAME>Macritchie</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><EMAIL_1>karine.macritchie@googlemail.com</EMAIL_1><EMAIL_2>kmacritchie@yahoo.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>c/o Ms Caroline Loveland, Centre for Affective Disorders, Institute of Psychiatry</DEPARTMENT><ORGANISATION>King&#8217;s College</ORGANISATION><ADDRESS_1>Denmark Hill</ADDRESS_1><CITY>London</CITY><ZIP>SE5 8AF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="7496" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Geddes</LAST_NAME><POSITION>Senior Clinical Research Fellow and Professor of Epidemiological Psychiatry, Honorary Consultant Psychiatrist Oxford Mental Healthcare NHS Trust</POSITION><EMAIL_1>john.geddes@psych.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Oxford/Warneford Hospital</ORGANISATION><CITY>Oxford</CITY><ZIP>OX3 7JX</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 226480</PHONE_1><FAX_1>+44 1865 793101</FAX_1></ADDRESS></PERSON><PERSON ID="z1307291024191974641646528726740" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jan</FIRST_NAME><LAST_NAME>Scott</LAST_NAME><POSITION>Professor of Psychological Medicine</POSITION><URL>http://www.ncl.ac.uk/ion/staff/profile/jan.scott#tab_profile</URL><ADDRESS><DEPARTMENT>Academic Psychiatry</DEPARTMENT><ORGANISATION>Newcastle University</ORGANISATION><CITY>Newcastle Upon Tyne</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="19510" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>D</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Haslam</LAST_NAME><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><CITY>Vancouver</CITY><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="13374" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mauricio</FIRST_NAME><LAST_NAME>Silva de Lima</LAST_NAME><SUFFIX>M.D. Ph.D.</SUFFIX><POSITION>Vice President</POSITION><EMAIL_1>msilvadelima@yahoo.com.br</EMAIL_1><EMAIL_2>limama@lilly.com</EMAIL_2><MOBILE_PHONE>+65 02 559 681</MOBILE_PHONE><ADDRESS><DEPARTMENT>US Medical Affairs</DEPARTMENT><ORGANISATION>Genentech</ORGANISATION><ADDRESS_1>1 DNA Way</ADDRESS_1><CITY>South San Francisco</CITY><ZIP>94080-4990</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 65 04 673 851</PHONE_1><FAX_1>+1 65 07 424 883</FAX_1></ADDRESS></PERSON><PERSON ID="13150" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guy</FIRST_NAME><LAST_NAME>Goodwin</LAST_NAME><POSITION>WA Handley Professor of Psychiatry</POSITION><EMAIL_1>guy.goodwin@psych.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Department of Psychiatry</ADDRESS_1><ADDRESS_2>Warneford Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 7JX</ZIP><REGION>Oxon</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 226451</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-05 23:09:02 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 10/5/01&lt;/p&gt;&lt;p&gt;New studies sought but none found: 9/25/01&lt;/p&gt;" NOTES_MODIFIED="2008-11-05 23:09:02 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="8" MONTH="9" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="9" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="8" MONTH="9" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-06-19 12:06:31 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-05 23:08:03 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-05 23:08:03 +0000" MODIFIED_BY="[Empty name]">Valproate for acutre mood episodes in bipolar disorder</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-05 23:07:06 +0000" MODIFIED_BY="[Empty name]">
<P>This systematic review investigated the efficacy and acceptability of valproate compared to that of placebo, lithium, carbamazepine, olanzapine and haloperidol in the treatment of acute episodes of bipolar disorder. Ten randomised studies were included in the review: all examined patients with mania. Valproate was more effective than placebo in the treatment of mania. There was no significant difference between efficacy in valproate and lithium or between valproate and carbamazepine, but there were fewer data on these comparisons and so these questions remain unanswered. The evidence suggests that valproate may be less effective in reducing manic symptoms than olanzapine but may cause less sedation and weight gain. There remains a need for more trials comparing medicines in treating all affective episodes.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Valproate has become a leading adjunctive and alternative treatment to lithium in bipolar disorder.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy and acceptability of valproate in acute episodes of bipolar disorder.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Registers and databases:</P>
<P>Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registrar (version 2-2002) <BR/>Cochrane Controlled Clinical Trials Register (3-2002)<BR/>Medline (1966-January 1999 )<BR/>PsychLit (1996-June 1999)<BR/>Embase (1980-January 1999)</P>
<P>Reference lists of relevant papers/books.</P>
<P>Trial authors, experts and pharmaceutical companies.</P>
<P>Handsearches (specialist journals and conference proceedings, listed below)</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing valproate with placebo and other medications for any acute episode. Bipolar patients, male and female, of all ages were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data extraction and methodological quality assessment were each performed independently by two reviewers. For analysis, relative risk was used for binary efficacy outcomes and the weighted mean difference or standardised mean difference used for continuously distributed outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Ten trials compared valproate with other interventions in mania. None examined depression or mixed affective episodes. Data were extracted on 'failure to respond by the end of the study' (i.e.less than 50% reduction in Young Mania Rating Scale or SADS-S mania scale). Three trials (316 participants) compared valproate with placebo. Three trials (158 participants) compared valproate with lithium. Two trials (363 participants) compared valproate with olanzapine. One trial (36 participants) compared valproate with haloperidol. Two trials (59 patients) compared valproate with carbamazepine. </P>
<P>Treatment acceptability was estimated by the 'total number withdrawing from the study'. Three trials (321 patients) compared valproate and placebo, two (144 patients) compared valproate with lithium. One study (30 patients) compared valproate and carbamazepine. Pooled relative risks ( 95% confidence intervals) were calculated using fixed effect. </P>
<P>Valproate was more efficacious than placebo (RRR 38%; RR 0.62; 95% C.I. 0.51 to 0.77) in the treatment of mania. There was no significant difference between valproate and lithium (RRI 5%; RR 1.05; 95% C.I. 0.74-1.50) or between valproate and carbamazepine (RRR 34%; RR 0.66; 95% C.I. 0.38 to 1.16). Valproate was less effective than olanzapine (failure to achieve clinical response; RRI 25%; RR 1.25, 95% C.I. 1.01 to 1.54; average of 2.8 point less change on the Mania Rating Scale (95% CI 0.83 to 4.79). There were no significant differences in those withdrawing from the study.<BR/> </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is consistent, if limited, evidence that valproate is an efficacious treatment for acute mania. Valproate may be less efficacious than olanzapine. More, rigorously designed, trials over the full range of acute affective episodes are required.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Bipolar disorder is amongst the top thirty causes of worldwide disability (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>). Its recurrent episodes produce lasting destructive effects on sufferer's psychological, occupational and social welfare. Mood stabilisers are the cornerstone of pharmacological intervention in this disorder, both in the treatment of acute episodes and in prophylaxis. They have been defined as medications which 'alleviate the frequency and/or intensity of manic, depressive and mixed episodes in patient with bipolar disorder and further, do not increase the frequency or severity of any of the subtypes or course variables of bipolar disorder' (<LINK REF="REF-Bowden-1996" TYPE="REFERENCE">Bowden 1996</LINK>). </P>
<P>Lithium was the only mood stabiliser in common use for many years. It remains a first choice in the treatment of acute episodes of bipolar disorder (<LINK REF="REF-Sachs-2000" TYPE="REFERENCE">Sachs 2000</LINK>) and may have specific anti-suicidal effects (<LINK REF="REF-ThiesFlechtner-1996" TYPE="REFERENCE">ThiesFlechtner 1996</LINK>). However, the mood stabilising effects of lithium may be delayed and are frequently incomplete (<LINK REF="REF-Bowden-1996" TYPE="REFERENCE">Bowden 1996</LINK>). It is thought to be less effective in some subgroups, particularly patients with mixed affective states (<LINK REF="REF-McElroy-1992" TYPE="REFERENCE">McElroy 1992</LINK>; <LINK REF="REF-Keck-1995" TYPE="REFERENCE">Keck 1995</LINK>). These shortcomings, in addition to its narrow therapeutic window and unwanted side effects, often make lithium treatment unsatisfactory. The anticonvulsants valproate and carbamazepine have become the leading adjunctive and alternative treatments to lithium in bipolar disorder. In Europe, valproate has been used in the treatment of acute mania since 1966 (<LINK REF="REF-Lambert-1966" TYPE="REFERENCE">Lambert 1966</LINK>). It is unclear whether they too have antisuicidal effects. </P>
<P>The adverse effects of valproate include gastro-intestinal effects, neurological symptoms such as tremor, sedation and ataxia (especially with the concomitant administration of other anticonvulsants and neuroleptics), alopecia, lethargy, dizziness and haematological dysfunction. Asymptomatic elevation in liver enzymes may occur. Pancreatitis and hepatotoxicity are rare but potentially serious and fatal complications (<LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>). Teratogenicity has been reported in the form of neural tube defects associated with first trimester use (<LINK REF="REF-Jeavons-1982" TYPE="REFERENCE">Jeavons 1982</LINK>). Congenital heart lesions, digital anomalies, oral clefts and craniofacial dysmorphic features may also occur (<LINK REF="REF-Battino-1996" TYPE="REFERENCE">Battino 1996</LINK>).</P>
<P>Valproate has been recommended as treatment for acute episodes of mania and depression in bipolar disorder (<LINK REF="REF-Sachs-2000" TYPE="REFERENCE">Sachs 2000</LINK>; <LINK REF="REF-Maudsley-2001" TYPE="REFERENCE">Maudsley 2001</LINK>). It was approved by the United States Food and Drug Administration for use in this context (<LINK REF="REF-FDA-1995" TYPE="REFERENCE">FDA 1995</LINK>). Valproate semisodium (Depakote) was licensed for the acute treatment of mania in the United Kingdom in 2001. </P>
<P>Valproate (2-propylpentanoate) is available in several forms, including sodium valproate, valproic acid alone and Depakote (divalproex or valproate semi-sodium), a compound of sodium valproate and valproic acid. All forms circulate as the valproate ion. There are no trials directly comparing the efficacy of available forms. Methodologically rigorous studies comparing the pharmacokinetics, efficacy and tolerability of valproate and divalproex are required. For the purposes of this review, the generic term valproate is used to denote 2-propylpentanoic acid and its derivatives. </P>
</BACKGROUND>
<OBJECTIVES>
<P>1. To determine the efficacy of valproate: <BR/>1.1 in alleviating manic symptoms in acute episodes of bipolar disorder.<BR/>1.2 in alleviating mixed affective symptoms in acute episodes of bipolar disorder. <BR/>1.3 in alleviating depressive symptoms in acute episodes of bipolar disorder. <BR/>1.4 on patients' general health and social functioning as measured by global clinical impression.</P>
<P>2. To review the acceptability of treatment with valproate to patients, measured by numbers and reasons for dropping out of trials, compliance, and by reference to patients' expressed views regarding treatment. </P>
<P>3. To investigate the adverse effects of valproate treatment including the general prevalence of side effects. Specified unwanted effects were studied. </P>
<P>4. To determine mortality rates on valproate.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised trials comparing valproate in the treatment of acute affective episodes (manic, mixed affective or depressive episodes) with placebo or alternative drug treatment in bipolar affective disorder were considered for inclusion. Acute treatment was defined as treatment instituted specifically to alleviate symptoms of an existing acute episode. <BR/>Discontinuation trials, in which patients received valproate prior to randomisation (other than for short periods of stabilisation), were to be analysed separately. We have reported our findings on this aspect of methodology under 'methodological quality of the included trials'. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Males and females of all ages with a diagnosis of bipolar disorder corresponding to International Statistical Classification of Diseases (ICD 10) Code F31* (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>) and Diagnostic and Statistical Manual of Mental Disorders (DSM IV) 296* (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). All subtypes of bipolar disorder (rapid cycling- i.e. those suffering from four or more affective episodes per year, types I and II and other) were included; cyclothymia was excluded. Potentially, some trials might involve heterogeneous groups of subjects: in particular, they might include schizo-affective disorder and unipolar depressive disorder (diagnoses approximating to ICD 10 F25 and DSM 295.70, and ICD 10 F33 and DSM IV 296.3, respectively). Of the studies included in this review, all examined bipolar patients only.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Valproate in the treatment of acute manic, mixed affective or depressive episodes in the context of bipolar disorder compared with:<BR/>1. placebo <BR/>2. alternative mood stabiliser treatment<BR/>3. combination mood stabiliser treatment<BR/>4. other treatment, e.g. neuroleptic medication</P>
<P>Studies in which valproate was used as an adjunctive treatment in combination with another mood stabiliser were to be considered separately from the main analysis. However, trials in which adjunctive antipsychotic medication was used were to be included in the main meta-analyses.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The outcome measures which were stipulated in the original protocol are listed below for completeness. However, in general, the included trials did not report on the outcomes that were specified in the protocol. For efficacy, the most useful extractable outcome measure was 'numbers who failed to respond to treatment by the end of the study'. </P>
<P>1.1. In the original protocol, for manic episodes, efficacy of treatment was to be measured by:<BR/>Requirement for hospital admission.<BR/>Length of hospital admission.<BR/>Time to cessation of additional treatment for manic symptoms.<BR/>Changes in manic symptom rating scales.<BR/>Changes in psychotic symptom scales.</P>
<P>Similarly, for mixed affective episodes, efficacy of treatment was to be measured by:<BR/>Requirement for hospital admission.<BR/>Length of hospital admission.<BR/>Time to cessation of additional treatment for mixed affective symptoms. <BR/>Changes in symptom rating scales.<BR/>Changes in psychotic symptom scales.</P>
<P>For depressive episodes, efficacy of treatment was to be measured by:<BR/>Requirement for hospital admission.<BR/>Length of hospital admission.<BR/>Time to cessation of additional treatment for depressive symptoms.<BR/>Changes in symptom rating scales.<BR/>Changes in psychotic symptom scales. </P>
<P>2. General Health and Social Functioning was to be measured by:<BR/>Global impression of the clinician. <BR/>Global impression of the subject, family or significant others. </P>
<P>3. Acceptability of valproate treatment was to be measured by:<BR/>Subjects withdrawing from the treatment during the study period.<BR/>Subjects' reports of satisfaction or otherwise with treatment.</P>
<P>4. Adverse effects:<BR/>Numbers of subjects experiencing:<BR/>troublesome side effects<BR/>gastrointestinal side effects: anorexia, nausea, vomiting, dyspepsia, diarrhoea.<BR/>neurological complaints: tremor, sedation, ataxia, cognitive impairment.<BR/>dizziness.<BR/>alopecia.<BR/>lethargy.<BR/>haematological dysfunction.<BR/>pancreatitis.<BR/>evidence of hepatic dysfunction and hepatotoxicity.<BR/>weight gain.<BR/>cases of teratogenicity.</P>
<P>5. Mortality Rates.<BR/>Overall mortality rates during the study period.<BR/>Mortality excluding suicide and verdicts of undetermined death.<BR/>Mortality due to iatrogenic causes.<BR/>Suicide and verdicts of undetermined death.</P>
<P>Amendment to protocol made in view of lithium's anti-suicidal effects and lack of evidence for similar effects with valproate.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See CCDAN Collaborative Review Group Search Strategy (http://www.iop.kcl.ac.uk/IoP/CCDAN/Index.htm). </P>
<P>Electronic databases.<BR/>The Cochrane Collaboration Depression Anxiety and Neurosis Controlled Trials Register - CCDANCTR (version 2002-2) and CENTRAL/CCTR (Issue 3, 2002) were searched using the following search strategy:</P>
<P>(VALPROAT* or absenor or apilepsin or convulex or convulsofin or depa or depacon or depakene or depakin or depakine or depakote or selenica or valpro or depamag or depamide or deproic or depicon or divalproex or epilim or epival or ergel or leptilan or leptilanil or leptilen or orifil or orlept or mylproin)</P>
<P>To look for randomised controlled trials and relevant papers, the following databases were searched:</P>
<P>Medline: 1966-January 1999 using the following search algorithm:</P>
<P> 1 206 "Valproic-Acid"/ all subheadings <BR/> 2 239 valpro* <BR/> 3 0 apilepsin <BR/> 4 0 depakote <BR/> 5 1 depakene <BR/> 6 2 epilim <BR/> 7 0 epival <BR/> 8 0 convulex <BR/> 9 2 divalproex <BR/> 10 239 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 <BR/> 11 2556 randomized-controlled-trial in pt <BR/> 12 879 controlled-clinical-trial in pt <BR/> 13 0 "Randomized-Controlled-Trials"/ all subheadings <BR/> 14 1799 "Random-Allocation" <BR/> 15 2018 "Double-Blind-Method" <BR/> 16 0 "Single-Blind-Method" <BR/> 17 4963 #11 or #12 or #13 or #14 or #15 or #16 <BR/> 18 5610 clinical-trial in pt <BR/> 19 3853 explode "Clinical-Trials"/ all subheadings <BR/> 20 1092 (clin* near trial*) in ti, ab <BR/> 21 1815 ((singl* or doubl* or trebl* or tripl*) near (blind* or mask*)) in ti,ab <BR/> 22 343 "Placebos"/ all subheadings <BR/> 23 1687 placebo* in ti,ab <BR/> 24 3946 random* in ti,ab <BR/> 25 740 "Research-Design"/ all subheadings <BR/> 26 14280 ~18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 <BR/> 27 29730 tg=comparative-study <BR/> 28 7957 explode "Evaluation-Studies"/ all subheadings <BR/> 29 4467 "Follow-Up-Studies" <BR/> 30 1952 "Prospective-Studies" <BR/> 31 24957 (control* or prospectiv*or volunteer*) in ti,ab <BR/> 32 60004 #27 or #28 or #29 or #30 or #31 <BR/> 33 66676 #17 or #26 or #32 <BR/> 34 70588 (tg=animal) not (tg=human) <BR/> 35 46740 #33 not #34 <BR/> 36 59 #10 and #35 <BR/> 37 3 #10 and #11 <BR/> The searches above are from: A:\VALPSER.HIS. <BR/> 38 59 #36 <BR/> Searches and records above from: MEDLINE EXPRESS (R) years stated<BR/>* 39 469 #36 </P>
<P>Embase: 1980-January 1999</P>
<P>1 Controlled study/ 840054<BR/>2 Clinical trial/ 148197<BR/>3 Major clinical study/ 339501<BR/>4 Randomized controlled trial/ 36462<BR/>5 Double blind procedure/ 31179<BR/>6 Clinical article/ 356098<BR/>7 random$.ti,ab,hw. 162692<BR/>8 trial$.ti,ab,hw. 248196<BR/>9 compar$.ti,ab,hw. 1014147<BR/>10 control$.ti,ab,hw. 1356473<BR/>11 study.ti,ab,hw. 1782230<BR/>12 follow$.ti,ab,hw. 215755<BR/>13 clinic$.ti,ab,hw. 1278321<BR/>14 blind$.ti,ab,hw. 82061<BR/>15 placebo$.ti,ab,hw. 76650<BR/>16 doubl$.ti,ab,hw. 143983<BR/>17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 3146404<BR/> or 13 or 14 or 15 or 16 <BR/>18 Animal/ 1842<BR/>19 Nonhuman/ 950723<BR/>20 18 or 19 951968<BR/>21 Human/ 1875034<BR/>22 20 and 21 123566<BR/>23 20 not 22 828402<BR/>24 17 not 23 2568100<BR/>25 Valproic acid/ 11593<BR/>26 valpro$.ti,ab,hw. 12250<BR/>27 apilepsin.ti,ab,hw. 0<BR/>28 depakote.ti,ab,hw. 22<BR/>29 depakene.ti,ab,hw. 32<BR/>30 epilim.ti,ab,hw. 14<BR/>31 epival.ti,ab,hw. 1<BR/>32 convulex.ti,ab,hw. 15<BR/>33 divalproex.ti,ab,hw. 175<BR/>34 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 12257<BR/>35 34 and 24 6403<BR/>36 exp Manic depressive psychosis/ 6178<BR/>37 bipolar.mp. [mp=title, abstract, heading word, trade name, 10579<BR/> manufacturer name] <BR/>38 36 or 37 14194<BR/>39 35 and 38 408<BR/>40 from 39 keep 1-200 200<BR/>41 from 39 keep 1-200 200</P>
<P>PsychLit: 1996-June 1999 </P>
<P>1 28456 random* <BR/> 2 36404 singl* <BR/> 3 11227 doubl* <BR/> 4 864 tripl* <BR/> 5 17 trebl* <BR/> 6 12964 blind* <BR/> 7 5215 mask* <BR/> 8 6814 (#2 or #3 or #4 or #5) near (#6 or #7) <BR/> 9 1540 crossover <BR/> 10 424 cross-over <BR/> 11 10639 versus <BR/> 12 241877 vs <BR/> 13 267409 #1 or #8 or #9 or #10 or #11 or #12 <BR/> 14 284 "Valproic-Acid" in DE <BR/> 15 670 valpro* <BR/> 16 0 apilepsin <BR/> 17 5 depakote <BR/> 18 3 depakene <BR/> 19 0 epilim <BR/> 20 0 epival <BR/> 21 1 convulex <BR/> 22 108 divalproex <BR/> 23 719 valpro* or apilepsin or depakote or depakene or epilim or epival or convulex or divalproex <BR/> 24 719 #23 or #14 <BR/> The searches above are from: A:\SEARCH.HIS. <BR/>* 25 199 #13 and #24 </P>
<P>Lilacs and Psyndex were searched only for randomised controlled trials through the CCDANCTR.</P>
<P>The reference lists of all randomised controlled trials and relevant papers thus identified were searched. The journals Comprehensive Psychiatry and Bipolar Disorders were handsearched. The annual conference proceedings of the American Psychiatric Association (2000 and 2001) and the British Association for Psychopharmacology (1999-2001) were also handsearched. (The results of the search proceedings of the American Psychiatric Association Annual Conference (1999) will be included in the next revision). </P>
<P>Personal communication.<BR/>The authors of significant papers over the last five years were identified from authorship lists. They, and other experts in the field, were contacted and asked for their knowledge of other studies, published or unpublished, relevant to the review. A total of eighty-nine authors and experts were approached. Twenty-one pharmaceutical companies marketing valproate products were requested to provide relevant published and unpublished data (see CCDAN group policy). We received seventeen replies from these enquiries. </P>
<P>No language restriction was applied within the limitations of the search tools.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>A) Selection of trials.<BR/>Studies found through the search strategy were checked to ensure they met the previously defined inclusion criteria by two reviewers (KM and JG). </P>
<P>B) Quality assessment. <BR/>Two reviewers independently assessed the methodological quality of the included studies (DH and JS). The reviewers were kept blind to the authorship and source of the papers by removing the authors and journal details from the articles. Quality was assessed according to the Cochrane criteria for quality assessment (<LINK REF="REF-Sackett-1997" TYPE="REFERENCE">Sackett 1997</LINK>). This pays particular attention to the adequacy of the randomisation procedure. On this basis, studies were given a quality rating of A (adequate), B (unclear) and C (inadequate). If the raters disagreed, the final rating was made by consensus with the involvement, if necessary, of another member of the review group. In addition, other aspects of quality such as blinding and reporting of withdrawals and dropouts are described in the text. Where inadequate details of randomisation and other characteristics of trials were provided, the authors were contacted in order to obtain further information. </P>
<P>C) Data Extraction. <BR/>Two reviewers (KM and JG) independently extracted data concerning participant characteristics, intervention details (including whether or not the study was of discontinuation design) and outcome measures from the included studies. There were no examples of non-concurrence.</P>
<P>D) Data Analysis. <BR/>Data were entered into Revman 4.1 software by two reviewers (KM and JG). <BR/>For binary efficacy outcomes, a relative risk (with 95% confidence intervals) was calculated using a fixed effects model. Heterogeneity between studies was assessed using the Q statistic (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and also by visual inspection. Random effects models were used to investigate the sensitivity of results to the choice of statistical method. Fixed effects results are presented unless the use of a random effects model materially changed the results. For continuously distributed outcomes, the weighted mean difference or standardised mean difference was calculated as appropriate. We used intention-to-treat data when available. Where this was not possible, end-point data for trial completers were used. Skewness of data was assessed using standard methods (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). </P>
<P>Non-quantitative data were presented descriptively. Outcomes concerning relapse/recurrence of affective disorder were to be analysed excluding data from studies of discontinuation design: data from these studies were to be analysed separately, to assess the effects of valproate discontinuation, but no such studies were found. There were insufficient data to perform sensitivity analyses excluding studies of lower methodological quality to assess the robustness of the results. It was not possible to do sub-group analyses in patients with specific diagnostic subtypes (e.g. mixed affective episodes, affective disorder with psychotic features, schizo-affective disorder, recurrent unipolar depression) or in patients who had previously failed to respond to mood stabilisers.</P>
<P>Relative risk ratios were calculated. When a RR is below 1, this favours valproate when the outcome is negative - or harmful. Percentage relative risk reductions (RRR) or relative risk increases (RRI) are presented for categorical outcomes. The percentage relative risk reduction (or increase) provides a measure of the proportion of the risk that occurred on the comparator intervention which would be avoided (or increased) with valproate. When the outcome is a benefit, the metric becomes Relative Benefit Increase (RBI) or reduction (RBR). Weighted mean differences are presented for continuous outcomes. </P>
<P>For the purposes of this review, we did not seek directly to compare different formulations of valproic acid because we were focusing on the main effect in comparisons with other treatments. However, if we encountered statistical significant heterogeneity between trials, then we planned to consider the effects of the formulation of valproic acid used. No such heterogeneity arose. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>We found ten trials that met the inclusion criteria for this review. All trials led to published reports. Eight trials assessed the efficacy of valproate or its derivatives in the treatment of patients with acute mania. We found no randomised controlled trials examining its efficacy in depressive episodes. Two studies (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK> and <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>) resulted in the publication of subgroup analyses on mixed mania (Clothier et al, 1992; Swann et al, 1997). </P>
<P>Two trials compared valproate with placebo: <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>used divalproex sodium; <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> used sodium valproate as adjunctive treatment to a neuroleptic. One trial compared divalproex with lithium and placebo (<LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>) and one compared valproate with lithium alone (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK>). Two trials compared valproate (divalproex) with olanzapine (<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>; <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK>) and one trial compared an oral loading dose of divalproex with haloperidol (<LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>). <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>) compared divalproex with lithium and carbamazepine in children and adolescents with bipolar disorder. <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> compared valproic acid with carbamazepine. </P>
<P>The objective of one trial (<LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK>) was the comparison of the safety and tolerability of accelerated-loading with non-loading doses of divalproex sodium and with lithium, It did not contribute to the efficacy meta-analysis because no outcome data were given. </P>
<P>All except one of the trials followed patients from the point of randomisation until they improved, left the study (due to lack of response, non-compliance or intolerable adverse effects) or completed the trial period. The exception was <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>, who examined oral loading of divalproex compared with haloperidol over a six-day period. Six trials used valproate doses approximating to 'oral loading' , i.e. 20mg/kg (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK>, <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>, <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>, <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>, <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK>)). Four trials used starting doses substantially lower than that, with increments in dose during the trial period (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>; <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> ; <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> and <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>), potentially resulting in comparatively delayed efficacy. The trials used a range of serum valproate levels from 50-150 micrograms per millilitre. Therapeutic serum levels for anticonvulsants in bipolar disorder have not been firmly established. </P>
<P>Four trials await further assessment because more detailed information regarding randomisation or some other aspect of methodology is sought (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>; <LINK REF="STD-Morinigo-1992" TYPE="STUDY">Morinigo 1992</LINK>; <LINK REF="STD-Tiangin-1995" TYPE="STUDY">Tiangin 1995</LINK>, <LINK REF="STD-Goswami-2001" TYPE="STUDY">Goswami 2001</LINK>): we have requested further information from the authors. These studies were comparisons of valproate with placebo (<LINK REF="STD-Tiangin-1995" TYPE="STUDY">Tiangin 1995</LINK>), with lithium or carbamazepine treatment (<LINK REF="STD-Goswami-2001" TYPE="STUDY">Goswami 2001</LINK>), with carbamazepine only (<LINK REF="STD-Morinigo-1992" TYPE="STUDY">Morinigo 1992</LINK>), and with lithium and verapamil (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>). <LINK REF="STD-Tiangin-1995" TYPE="STUDY">Tiangin 1995</LINK> was excluded from the meta-analysis, pending more information on the primary outcome measure, the 1981 Chinese Medical Society Psychiatric Division Rating Scale. </P>
<P>Initial doses of valproate. <BR/>Six trials used valproate doses approximating to 'oral loading' of 20mg/kg (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK> , <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>, <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>, <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>, <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK>)). Four trials used starting doses substantially lower than that, with increments in dose during the trial period (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>, <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK>; <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>.</P>
<P>Outcome measures used in the trials. <BR/>Studies varied in their definition of improvement. However, all the studies used continuous measures of manic symptoms as main outcome measures in the assessment of clinical improvement: an arbitrary relative improvement of a 50% or greater reduction from baseline in the scale rating mania was taken to signify a clinical response (<LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>; <LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK>; <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>; <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>; <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>; <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>; <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>; <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK>; <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>. This is a commonly used approach, but it has several problems. First, an improvement in scale rating may not reflect a clinically useful improvement. Also, the magnitude of a 50% relative improvement in scale rating varies depending on the absolute value of the original score: patients with the same percentage improvement may have exhibited markedly different clinical responses. Finally, there may be differences in what is understood to be the severity of illness represented by a given score between those conducting the trials and those interpreting their reports. There follows a brief account of the scales used in the provision of data included in this review.</P>
<P>Scales assessing mental state.<BR/>Young Mania Rating Scale (<LINK REF="REF-Young-1978" TYPE="REFERENCE">Young 1978</LINK>). <BR/>This scale, used by <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK>; <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>; <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>; <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>; <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>; <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>, <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>, and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK> has 11 items which are rated after a clinical interview. Irritability, speech rate and amount, content of thought and disruptive behaviour items are given extra weight in the total by being scored from 0-8, whereas the remaining items are scored from 0-4. Higher scores indicate more symptoms. </P>
<P>SADS-C Manic Syndrome Subscale (<LINK REF="REF-Endicott-1978" TYPE="REFERENCE">Endicott 1978</LINK>).<BR/>
<LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK> defined a 50% reduction in this score as a favourable outcome. The SADS scale was developed with the primary aim of differentiating between schizophrenia and mood disorders. The scale makes use of collateral information and past history. The SADS-C scale is adapted to measure change over time. The manic syndrome subscale score examines elevated mood, sleep, energy activity and grandiosity. </P>
<P>Scales assessing global state.<BR/>Clinical Global Impression (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).<BR/>
<LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK> used this scale which assesses both severity of illness and clinical improvement by comparing the condition of the subject standardised against others with the same diagnosis. The seven point scoring system is usually employed, with low scores showing decreased severity and overall improvement. <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> used a modification of the Clinical Global Impressions Scale for use in bipolar illness (BP): the CGI-BP (<LINK REF="REF-Spearing-1997" TYPE="REFERENCE">Spearing 1997</LINK>). Modifications include the correction of perceived inconsistencies in scaling, detailed definitions of illness severity and change, the inclusion of time frames and the separation of the assessment of improvement in illness from the assessment of the adverse effects of treatment. Previous phases of illness are also used as comparators for the assessed period. A CGI score of greater than 3 is often taken to indicate a clinical response. </P>
<P>The Global Assessment Scale (GAS) (<LINK REF="REF-Spitzer-1970" TYPE="REFERENCE">Spitzer 1970</LINK>).<BR/>Five trials used this scale: <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>, <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>, <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> and <LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK>. The Global Assessment Scale evaluates the overall functioning of a patient (<LINK REF="REF-Spitzer-1970" TYPE="REFERENCE">Spitzer 1970</LINK>). The participant's general functioning is given a score following consideration of any behavioural disturbance, levels of distress, social functioning, self-care, impulsivity and reality testing. Higher scores indicate a higher level of functioning. </P>
<P>Assessment of adverse effects.<BR/>In general, adverse effects experienced by participants were either listed in tables with statements of frequency, or were described in the text. <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> , who studied sodium valproate as an adjunctive treatment to neuroleptic medications and <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> who compared divalproate with olanzapine, used scales to measure extra-pyramidal effects.</P>
<P>Simpson-Angus Scale. <BR/>
<LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> and <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> used this scale which assesses extra-pyramidal symptoms (signs relating to the abnormality of gait, muscle rigidity and resistance to movement, the glabellar tap, tremor and salivation). These items are scored from 0-4. The score increases with the severity of symptoms.</P>
<P>The Barnes Akathisia Scale.<BR/>
<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> used this scale which comprises an observer's rating of a patient's restlessness, the patient's awareness of symptoms and the distress caused by restlessness. Each item is scored from 0-3. This score is supplemented with a global clinical assessment of akathisia scoring from 0-5. Higher scores reflect greater severity of symptoms.</P>
<P>Abnormal Involuntary Movement Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).<BR/>This scale was used by <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>. It scores facial and oral movements (4 items), movements of the limbs and the trunk (3 items), dental problems (2 items) and global judgements such as the severity of abnormal movements, their resultant incapacitation and subject's awareness of abnormal movements (3 items). Each item, with the exception of dental problems, is scored on a five point scale, from normal to severe.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>In the original protocol, the Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) was to be used to rate trial quality. Due to doubts over the validity of the scales used (<LINK REF="REF-Juni-1999" TYPE="REFERENCE">Juni 1999</LINK>) we decided not to use the Jadad scale, but to describe methodological aspects of trials that have been shown to be empirically related to bias. There were no disagreements between reviewers on the rating of trial quality or in the selection of trials.</P>
<P>Randomisation and concealment of allocation.<BR/>All trials were described as randomised. Using the Cochrane Criteria which rate the adequacy and concealment of random allocation, all trials were rated as B (unclear).</P>
<P>Blinding.<BR/>The clinicians and patients were kept blind to treatment allocation in all the studies except <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>, in which only the assessor was blinded. However, it is possible that both the assessors and patients previously in receipt of the study medications may have been unblinded by the distinctive adverse effect profile of the trial drugs.</P>
<P>Handling of withdrawals: Intention to treat analyses and use of last observation carried forward.<BR/>Two of the trials (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK> and <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>) included all randomised patients in the analysis and the patients were analysed according to the group to which they were allocated. <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> included all randomised patients in the primary analysis with the exception of three patients from one centre who were excluded because the centre failed to recruit sufficient patients. <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK> included all those who had completed at least seven days of the twenty-one day treatment in their analysis, but did not report on those who dropped out. <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> reported on drop out rates because of lack of efficacy, non-compliance and 'miscellaneous reasons', but it is unclear if they used an intention-to-treat analysis. <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> excluded two patients in the valproate group and one patient allocated to placebo from the analysis due to missing data. <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> included all of the one hundred and twenty five patients allocated to olanzapine in the analysis but three of the one hundred and twenty six patients who were allocated to valproate treatment were excluded because they withdrew early - this is therefore a modified ITT analysis. <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> reported on all thirty patients from each group. Three patients from each group withdrew during the trial and the reasons for their withdrawal were recorded. <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> reported on those who dropped out of each group and provided reasons for cessation in some, but not all, of those who withdrew early. They used a modified intention-to-treat analysis, including forty one subjects who completed at least one week of treatment. All the studies that performed ITT analyses used 'last observation carried forward' (LOCF) techniques to estimate endpoint symptom scores for participants who withdrew early. The LOCF approach is usually thought to give a conservative estimate of the effectiveness of a treatment in an acute illness, but when withdrawal is non-random (i.e. associated with one of the treatments - perhaps through failure of blinding) it can give a biased estimate of that treatment effect. The withdrawal rates from the studies are variable ( &gt;50% of placebo treated patients withdrew in <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> but less than 3% in <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>). The use of LOCF introduces more uncertainty and potential for bias the higher the withdrawal rate and this should be considered when interpreting the findings of this review.</P>
<P>Numbers of participants.<BR/>Most of the included studies were too small to reliably detect moderate but clinically important treatment effects. Their small size limits their ability to detect small differences in acceptability or differences in the rates of rare outcomes and rendered them prone to potential confounding by baseline differences between groups. None of the published accounts reported power calculations. </P>
<P>Selection of participants.<BR/>The participants of all the trials except one were adult in-patients who met operationally defined diagnostic criteria for acute mania. <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> studied bipolar I or II patients from an out-patient clinic with mixed or manic episodes. Their patients were between 8 and 18 years of age. </P>
<P>Inevitably, the participants of all the trials were selected in one way or another. None of the trials provided a clear indication of the manner in which patients were selected for the trial as recommended by the CONSORT statement (<LINK REF="REF-Begg-1989" TYPE="REFERENCE">Begg 1989</LINK>). <LINK REF="REF-Licht-1996" TYPE="REFERENCE">Licht 1996</LINK> demonstrated the inherent difficulties of recruiting a representative sample of patients to trials in anti-manic treatment. The trials included in this review exhibited the same difficulties. The main problem was the tendency to exclude severely affected patients. Some of the trials mentioned that patients were able to give informed consent to participate, potentially excluding those with severe mania. <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> and <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> defined a manic episode on the basis of a low threshold Young Mania Rating Scale Score of 14 or more. Another difficulty was a tendency to select on the grounds of previous experience of trial medications. <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK> studied patients who had failed to respond to lithium and those who were intolerant to it. Several of the trials (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>, and <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>) excluded those with previous experience of valproate. <LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK> did not include anyone with previous experience of valproate, although it was not an exclusion criterion. <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> did not discuss previous experience of valproate in their patients. <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> and <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> did not report on previous exposure to mood stabilisers. <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> excluded those who had previously experienced severe adverse effects on lithium, and those who had shown an intolerance to valproate or lithium respectively. <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> did not specify the exclusion criteria in the short published account of their trial. Finally, one trial was highly selective with regard to female subjects: <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK> included only those women who were post-menopausal or surgically sterilised. <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> excluded women who were pregnant or on hormonal contraception.</P>
<P>Diagnosis.<BR/>Standardised diagnostic tools and operationally defined diagnostic criteria were used in all the trials. </P>
<P>Discontinuation effects.<BR/>Although some authors dispute its existence (<LINK REF="REF-Schou-1993" TYPE="REFERENCE">Schou 1993</LINK>), it is widely accepted that 'rebound mania' occurs in some bipolar patients on discontinuation of lithium (<LINK REF="REF-Suppes-1991" TYPE="REFERENCE">Suppes 1991</LINK>, <LINK REF="REF-Goodwin-1994" TYPE="REFERENCE">Goodwin 1994</LINK>). In acute treatment trials, discontinuation of lithium prior to the experimental phase might lead to exacerbation of mania, possibly affecting the observed response to the trial drug. It is not clear whether a similar effect exists on anticonvulsant withdrawal.</P>
<P>None of the trials appeared to have given specific consideration to this phenomenon. However, most trials reported the withdrawal of psychotropic medication prior to randomisation. <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK> described a washout period where medication was withdrawn prior to entry in the study. <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> specified that plasma lithium was undetectable prior to randomisation, and that there was no significant difference between the number of patients previously treated with lithium in the period leading up to the study in each of the treatment groups. <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK> recorded that there was no significant difference between the groups in any on the medications they received prior to the study. <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> excluded patients who had received treatment for the index manic episode, but did not address the issue of medication prior to its onset. In <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> patients had undergone a two week period where all medications were tapered off prior to randomisation. 79% of the group were on psychotropic medication, but prior mood stabiliser treatment was not detailed in the published account. <LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK> and <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK> reported a washout period, but did not describe the distribution of those undergoing lithium withdrawal amongst the treatment groups. <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> described how patients previously treated with lithium or carbamazepine entered the trial only after a washout period, when serum levels of lithium were less than 0.4 mmol per litre and levels of carbamazepine were less than 2 mcg per millilitre. <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> reported a washout period of 72 hours for drugs including valproate and lithium, prior to commencement of trial medication and gave maximum serum levels permitted prior to commencing the study. <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK> did not detail previous medication or its discontinuation in their published account. </P>
<P>Use of rescue medication and adjustment of dose of investigational drug.<BR/>Several lithium trials have been criticised as the dosage of a trial drug was altered in response to clinical deterioration (<LINK REF="REF-Moncrieff-1997" TYPE="REFERENCE">Moncrieff 1997</LINK>). <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK> allowed the adjustment of mood stabiliser dose by non-blinded investigators. However, all adjustments were made to achieve appropriate drug serum levels: none was made in response to clinical presentation. <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> also titrated doses to reach predetermined serum levels during the study period. <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> increased the dose of carbamazepine and valproate in their study at weekly intervals throughout the trial period until the subject exhibited clinical improvement or until maximum serum levels were attained. <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> adjusted doses of valproate and olanzapine based on clinical response and on plasma levels. <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> used a fixed dose of valproate throughout the study. <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> allowed adjustments in doses of lithium but not valproate. It is not clear from the published account whether adjustments in doses of lithium were in response to clinical presentation or according to serum levels. All trials used other psychotropic agents as rescue medication.</P>
<P>Publication bias.<BR/>The presence of publication bias was not examined in this systematic review because there were insufficient trials in each intervention category to allow meaningful formal assessment using funnel plots. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Description of search results.</P>
<P>We found ten randomised controlled trials which are included in the meta-analysis. Thirty two studies, listed in the Excluded Studies Table , did not meet our inclusion criteria for the reasons given. Five studies await further assessment. One study (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>) was found through reference checking; <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>, <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>, <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK> and <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK> were originally identified through abstract hand searches.</P>
<P>In general, the trials did not report on the outcomes that were pre-specified in the protocol of this review. Where possible, we extracted data that best approximated to these outcomes. Outcomes of clear relevance to patients and clinicians, in particular, patient's and their relatives' attitudes to treatment, their ability to return to work and resume normal social functioning, and the effects of treatment on suicidality, were not reported in the included studies. </P>
<P>We anticipated that some trials might combine acute treatment and maintenance phases, and, where possible, we planned to separate these data for the purposes of this review. However, we found that trials including acute and maintenance phases published acute phase results separately. </P>
<P>To aid in the interpretation of results, the reader is referred to the method section above for discussion of the statistical methods used.</P>
<P>1. Efficacy of valproate in the treatment of acute manic episodes in bipolar disorder.<BR/>For efficacy, the most useful extractable outcome measures were: changes in mania symptom rating scale scores from baseline to follow-up, numbers who failed to respond to treatment by the end of the study and numbers dropping out due to deterioration or failure to respond. </P>
<P>a. Valproate vs. Placebo. <BR/>Failure to respond by the end of the study: categorical outcomes.</P>
<P>(i) Less than or equal to 50% reduction on YMRS or SADS-C mania scale.<BR/>Three trials (316 participants) contributed to the comparison of the efficacy between valproate and placebo using the outcome 'failure to respond by the end of the study' ( <LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>). Valproate was more efficacious than placebo (RRR 38%; RR 0.62; 95% C.I. 0.51 to 0.77). As described earlier, the assessment of clinical response involved the use of LOCF analyses. <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK> had a low drop-out rate compared to <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>, yet the estimates of effect from these two trials were remarkably similar. There is therefore no indication that the use of LOCF in the context of the relatively high drop-out rate seriously biased the results of <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>.</P>
<P>(ii) CGI Change score of 3+.<BR/>One trial with 133 participants (<LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>) contributed to the comparison of the efficacy between valproate and placebo using this outcome measure. The difference between valproate and placebo was just statistically significant (RRR 34%; RR 0.66, 95% C.I. 0.43 to 1.00).</P>
<P>(iii)Withdrawal because no longer requiring hospital admission. <BR/>Two trials contributed to this comparison (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>; <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>). There was no significant difference between valproate and placebo in this respect (RBI 224%; RR 3.24; 95% C.I. 0.80 to 13.17). </P>
<P>b. Valproate v. lithium.<BR/>Failure to respond clinically by the end of the study: categorical outcomes.</P>
<P>(i) Less than or equal to 50% reduction on YMRS or SADS-C mania scale.<BR/>Three trials (158 participants) provided data on this outcome measure (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>). There was no significant difference between the two medications in this respect (RRI 5%; RR 1.05; 95% C.I. 0.74 to 1.50).</P>
<P>(ii) Clinical Global Impression Change score of 3+(taken to represent a clinical response).<BR/>One trial with 28 participants (<LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>) contributed to the comparison of the efficacy between valproate and lithium using this outcome measure. There was no significant difference between valproate and lithium (RRI 11%; RR 1.11, 95% C.I. 0.58 to 2.14).</P>
<P>(iii) Withdrawal because no longer requiring hospital admission. <BR/>One study contributed to this comparison (<LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>). There was no significant difference between valproate and lithium (RRR 22%; RR 0.78 (95% C.I. 0.14 to 4.47.)</P>
<P>c. Valproate v. Carbamazepine. <BR/>Failure to respond clinically by the end of the study: categorical outcomes. </P>
<P>(i) Less than or equal to 50% reduction on YMRS or SADS-C mania scale.<BR/>Two trials (59 participants) compared the efficacy of valproate with carbamazepine (<LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>; <LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>) and provided data for this outcome measures. There was no significant difference in the numbers who failed to respond clinically by the end of the study (RRR 34%; RR 0.66; 95% C.I. 0.38 to 1.16). <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> with 28 children and adolescents compared valproate with carbamazepine efficacy by assessing those who 'failed to respond' using the CGI-change core of 3+. Again, there was no significant difference between the medications (RRR 13%; RR 0.87; 95% C.I. 0.50 to 1.50).</P>
<P>(ii) CGI Change score of 3+.<BR/>One trial with 28 participants (<LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> contributed to the comparison of the efficacy between valproate and lithium using this outcome measure. There was no significant difference between valproate and lithium (RRR 13%; RR 0.87, 95% C.I. 0.50 to 1.50).</P>
<P>d. Valproate v. olanzapine.</P>
<P>Change in mania symptoms from baseline to follow-up<BR/>Two trials with 363 participants ( <LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>; <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK>) compared valproate with olanzapine and reported changes on symptoms rating scales. Participants allocated to olanzapine experienced greater symptom reductions than those allocated to valproate (WMD 2.81, 95% CI 0.83 to 4.79)</P>
<P>Failure to respond clinically by the end of the study: categorical outcomes.</P>
<P>(i) Less than or equal to 50% reduction on YMRS or SADS-C mania scale.<BR/>One trial (251participants) compared valproate with olanzapine (<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>). There was a marginally significant difference between the drugs, in favour of olanzapine (RRI 27%; RR 1.27, 95% C.I. 0.99 to 1.62). </P>
<P>(ii) Failure to remit by the end of the study.<BR/>
<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK> with 248 participants, provided data for this comparison. There was a significant difference in favour of olanzapine (RRI 25%; RR 1.25; 95% C.I. 1.01 to 1.54)</P>
<P>e. Valproate v. haloperidol</P>
<P>Failure to respond clinically by the end of the study: categorical outcomes.</P>
<P>Less than or equal to 50% reduction on YMRS or SADS-C mania scale.</P>
<P>One trial compared valproate with haloperidol (<LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK>). This was a small trial comparing oral loading valproate to haloperidol over six days. An additional outcome measure of the duration of hospital admission in each group also showed no significant difference between the groups (Mean Difference 3.3 days; 95% C.I. -2.66 to 9.26).</P>
<P>2. General Health and Social Functioning.<BR/>Most information regarding global functioning was in the form of Global Assessment Scale changes. All the trials included some kind of global assessment by clinicians in the form of scales. None of the trials included scales allowing the self-rating of treatment outcomes by participants.</P>
<P>a. Valproate v. placebo.<BR/>Two trials (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>) provided sufficient information on the Global Assessment Score for analysis. There was a significant difference between valproate and placebo (WMD 7.77; 95% CI 2.54 to 13.00). <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> included mean changes in the GAS but without standard deviations.</P>
<P>b.Valproate v. lithium.<BR/>Only one study (<LINK REF="STD-Freeman-1992" TYPE="STUDY">Freeman 1992</LINK>) presented usable data on GAS (Mean Difference -9.30; 95% C.I. -22.78 to 4.18).</P>
<P>c. Valproate v. carbamazepine.<BR/>
<LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>, with 28 children and adolescents compared valproate with carbamazepine efficacy by assessing those who 'failed to respond' using the CGI-change core of 3+(<LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>). As reported above, there was no significant difference between the two interventions (RRR 13%; RR 0.87; 95% C.I. 0.50 to 1.50).</P>
<P>d. Valproate v. antipsychotic medication.<BR/>No data were available on global clinical outcome.</P>
<P>3. Acceptability of valproate treatment.</P>
<P>a. Valproate v. placebo.</P>
<P>Total number of subjects withdrawing from the study. <BR/>Three trials (321 participants) provided data on this outcome (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>). There was no significant difference between the numbers of patients dropping out of treatment in the valproate compared to the placebo group (RRI 95%; RR 1.95; 95% C.I. 0.66 to 5.71). </P>
<P>Total number of subjects withdrawing from the study due to intolerance.<BR/>Three studies (321 participants) provided data on this outcome (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>). There was no significant difference between the two groups (RRI 91%; RR 1.91; 95% CI 0,66 to 5.51).</P>
<P>b. Valproate v. lithium. <BR/>Total number of subjects withdrawing from the study. <BR/>Two studies (144 participants) provided data on this outcome (<LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>; <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK>). For the purposes of our review, to avoid double entry of the lithium group in our meta-analysis, we used the data from the non-loading valproate group in <LINK REF="STD-Hirschfeld-1999" TYPE="STUDY">Hirschfeld 1999</LINK> in our analysis. There was no significant difference between the two interventions (RRR 3%; RR 0.97; 95% C.I. 0.57 to 1.66).<BR/> <BR/>Total number of subjects withdrawing from the study due to intolerance.<BR/>One study (<LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK>) provided data on this outcome. There was no significant difference between the two groups (RRR48%; RR 0.52; 95% C.I. 0.14 to1.96).</P>
<P>c. Valproate v. carbamazepine.</P>
<P>Total number of subjects withdrawing from the study. <BR/>One study (30 participants) provided data on this outcome (<LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>). There was no significant difference between the two interventions (RRR 0%; RR 1.00; 95% C.I. 0.24 to 4.18). </P>
<P>Total number of subjects withdrawing from the study due to adverse effects<BR/>One study (30 participants) provided data on this outcome (<LINK REF="STD-Vasudev-2000" TYPE="STUDY">Vasudev 2000</LINK>). There were no study withdrawals. </P>
<P>d. Valproate v. antipsychotics.<BR/>Total number of subjects withdrawing from the study. <BR/>One study (251 participants) provided data on this outcome (<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>) There was no significant difference between the two interventions (RRI 8%; RR 1.08; 95% C.I. 0.50 to 2.36). </P>
<P>Total number of subjects withdrawing from the study due to adverse effects.<BR/>One study (251 participants) provided data on this outcome (<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>). There was no significant difference between the two interventions (RRR 9%; RR 0.91; 95% C.I. 0.51 to 1.59). </P>
<P>4. Specific adverse events.</P>
<P>a. Valproate v. placebo.<BR/>Three trials provided information on the occurrence of many adverse effects (<LINK REF="STD-Pope-1991" TYPE="STUDY">Pope 1991</LINK>, <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Muller_x002a_-1999" TYPE="STUDY">Muller* 1999</LINK>). Valproate was associated with significantly more dizziness (RRI 217%; RR 3.17; 95% C.I. 1.13 to 8.88). No other adverse effects showed a significant difference in frequency of occurrence.</P>
<P>b. Valproate v. lithium.<BR/>Two trials reported on these outcomes. <LINK REF="STD-Bowden-1994" TYPE="STUDY">Bowden 1994</LINK> and <LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK> provided data for meta-analyses on several specific adverse effects, but none showed a significant difference except fever . Valproate had significantly less fever than lithium (RRR 90%; RR 0.10; 95% C.I. 0.01 to 0.86). </P>
<P>c. Valproate v. carbamazepine.<BR/>Only one trial provided data on specific adverse effects on valproate v. carbamazepine therapy (<LINK REF="STD-Kowatch-2000" TYPE="STUDY">Kowatch 2000</LINK>), but no comparison showed a significant difference.</P>
<P>d. Valproate v. olanzapine<BR/>Two trials (363 participants) contributed data (<LINK REF="STD-Tohen-2000" TYPE="STUDY">Tohen 2000</LINK>, <LINK REF="STD-Zajecka-2002" TYPE="STUDY">Zajecka 2002</LINK>). Olanzapine was no more likely to cause movement disorders than valproate and olanzapine (akathisia: WMD -0.02 (-0.27, 0.23); AIMS: WMD -0.17 (95% CI -0.62 to 0.28)). Olanzapine cause more weight gain than valproate (WMD -2.14kg, 95% CI -2.65 to -1.62) - a substantial difference during the short duration of the trials. Valproate was associated with more cases of nausea than olanzapine (RRI 175%; RR 2.75; 95% C.I. 1.53 to 4.93) and less cases of increased appetite (RRR 80%; RR 0.2; 95% C.I. 0.06 to 0.67).Valproate was associated with less cases of dry mouth than olanzapine (RRR 81%; RR 0.19; 95% C.I. 0.09 to 0.39). Significantly larger numbers receiving olanzapine experienced sedation than those receiving valproate (RRR 45%; RR 0.55; 95% C.I. 0.41 to 0.76). </P>
<P>We found no reports of teratogenicity.</P>
<P>d. Valproate v. haloperidol</P>
<P>
<LINK REF="STD-McElroy-1996" TYPE="STUDY">McElroy 1996</LINK> provided data for the comparison with haloperidol (36 participants). Valproate was associated with fewer extra-pyramidal adverse effects than haloperidol (RRR 96%; RR 0.04; 95% C.I. 000 to 0.69). Valproate was associated with less cases of dry mouth than haloperidol (RRR 76%; RR 0.24; 95% C.I. 0.03 to 2.07). Haloperidol was not more likely to cause sedation than valproate (RRR 82%; RR 0.18; 95% C.I. 0.02 to 1.44).</P>
<P>5. Mortality.</P>
<P>There were no reports of deaths on patients on valproate in any of the studies. </P>
<P>We planned to consider heterogeneous effects of formulations as a possible explanation if we encountered statistically significant heterogeneity between trials, but none arose. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>All the trials in this review investigate valproate in the treatment of mania. The earlier trials are relatively small, but there are encouraging signs that in recent years, larger trials have been conducted. Most have some methodological shortcomings, which have been outlined in the description of methodological quality above. It is worth remembering that the medication used for the treatment of an acute episode may be continued for many weeks or months. Most of the trials are only 3 weeks in duration and so provide limited information for long-term treatment decisions. </P>
<P>Three trials contributed to the meta-analysis comparing valproate with placebo. The results were largely consistent across trials and the existing data suggest that valproate is more efficacious than placebo in the treatment of mania. However, the small total number of participants means that the existence of only a few undetected small neutral or negative trials might substantially change the estimates of effect. We found no trials investigating the efficacy of valproate in acute episodes of bipolar depression. There are fewer data on the relative efficacy of valproate and lithium and valproate and carbamazepine. At present, these questions remain unanswered. Currently, it is common practice to use antipsychotic medication (both typical and increasingly, atypical) in the treatment of acute manic episodes. There is evidence that olanzapine is superior to valproate in reduction of manic symptoms, although this may be at the cost of more sedation and weight gain. At present, the choice between valproate and typical and atypical antipsychotic medication may depend on the clinician's and the patient's view of the tolerability of various adverse effects. A review on the efficacy of olanzapine in bipolar disorder is currently underway (<LINK REF="REF-Rendell-2001" TYPE="REFERENCE">Rendell 2001</LINK>).<BR/>Our findings on the efficacy of valproate in mania are in agreement with recently published narrative reviews (<LINK REF="REF-Gilmer-2001" TYPE="REFERENCE">Gilmer 2001</LINK>; <LINK REF="REF-Bhana-2001" TYPE="REFERENCE">Bhana 2001</LINK>). </P>
<P>It is important to note that, due to ethical and practical considerations, severely ill and psychotic patients may not have been well represented in the available trials and so it is unknown if valproate is effective in more severe manic illness. The applicability of the findings of this systematic review to the spectrum of bipolar patients seen in clinical practice may therefore be limited and this should be born in mind when using the results. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Within the limitations of this review, there is consistent, if numerically limited, evidence from randomised trials that valproate is an efficacious treatment for acute mania. The relative efficacy of valproate compared to lithium and carbamazepine is unclear. Valproate may be less effective than olanzapine in reducing manic symptoms, but cause more sedation and weight gain.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More well designed, randomised controlled trials investigating the relative efficacy and acceptability of valproate in the treatment of the full range of acute affective episodes occurring in bipolar disorder are required. Future researchers should learn from existing trials and aim to include a wide range of participants to maximise the applicability to the spectrum of bipolar patients seen in clinical practice. </P>
<P>In view of the practical and ethical difficulties of the inclusion of a placebo group, especially for severely ill patient, future trials should focus on the comparison of valproate with other medications. Outcome measures of relevance to both patients and clinicians such as length of hospital stay, occupational and social assessments and reports of patient satisfaction should be included. To be reliable and useful, trials need to be larger than those completed to date and need to be designed to detect moderate but worthwhile benefits.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors are grateful to Dr Luk Ho for his help in the translation of Tiangin (1995) and to CCDAN and Wendy Roberts (Librarian, Addenbrookes' Medical School Library) for help in constructing and implementing the search strategy. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-06-19 12:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>JG has received research funding and support from Sanofi-Aventis and GlaxoSmithKline and is currently in discussion with several other companies that manufacture SSRIs about collaboration on planned independent trials and systematic reviews. MSL took up a position with Eli Lilly in 2003.</P>
<P>Please note that the current version of this review contravenes Cochrane's commercial sponsorship policy (revised 2014). An update of the review is underway and is scheduled for publication in 2016.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-11-05 23:08:37 +0000" MODIFIED_BY="[Empty name]">
<P>The updated version of this review will be submitted by December 2008.<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowden-1994" NAME="Bowden 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F et al</AU>
<TI>Efficacy of divalproex vs lithium and placebo in the treatment of mania</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<NO>12</NO>
<PG>918-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowden CL, Davis J, Morris D, Swann A, Calabrese J, Lambert M et al</AU>
<TI>Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania</TI>
<SO>Depression &amp; Anxiety</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>26-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR et al</AU>
<TI>Relation of serum valproate concentration to response in mania</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>765-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petty F, Rush J, Davis JM, Calabrese JR, Kimmel SE, Kramer GL et al</AU>
<TI>Plasma GABA predicts acute response to divalproex in mania</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>278-384</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J et al</AU>
<TI>Depression during mania: treatment response to lithium or divalproex</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1992" NAME="Freeman 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clothier J, Swann AC, Freeman T</AU>
<TI>Dysphoric mania</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC</AU>
<TI>A double-blind comparison of valproate and lithium in the treatment of acute mania</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<NO>1</NO>
<PG>108-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirschfeld-1999" NAME="Hirschfeld 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Russell JM</AU>
<TI>Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>12</NO>
<PG>815-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kowatch-2000" NAME="Kowatch 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M et al</AU>
<TI>Effect size of lithium, divalproex, and carbamazepine in children and adolescents with bipolar disorder</TI>
<SO>Journal of the American Academy of Child &amp; Adolescent Psychiatry</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>6</NO>
<PG>713-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElroy-1996" NAME="McElroy 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM</AU>
<TI>A randomised comparison of divalproex loading versus haloperidol in the initial treatment of acute psychotic mania</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<PG>142-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Muller_x002a_-1999" NAME="Muller* 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J</AU>
<TI>Valproate add-on therapy in acute manic episodes. A prospective, randomised, double-blind, placebo-controlled multicentre study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>195-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pope-1991" NAME="Pope 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pope HG, McElroy SL, Keck PE, Hudson JI</AU>
<TI>Valproate in the treatment of acute mania: A placebo controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<PG>62-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tohen-2000" NAME="Tohen 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Tohen M, Baker RW, Altshuler L, Zarate CA, Ketter TA, Milton DR et al</AU>
<TI>Olanzapine versus divalproex for ther treatment of acute mania</TI>
<SO>Stanley Foundation Conference on Bipolar Disorder September 21-22 2000 Amsterdam</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasudev-2000" NAME="Vasudev 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vasudev K, Goswami U, Kohli K</AU>
<TI>Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder</TI>
<SO>Psychopharmacology</SO>
<YR>2000</YR>
<VL>150</VL>
<PG>15-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Zajecka-2002" NAME="Zajecka 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW</AU>
<TI>A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<PG>1148-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Altamura-1986" NAME="Altamura 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Altamura AC, Basile MM, Cazullo CL</AU>
<TI>Valpromide (Depamide) in the treatment of acute psychotic states: An open clinical study</TI>
<TO>Le valpromide (Depamide) dans le traitement d'etats psychotiques aigus.</TO>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1986</YR>
<VL>86</VL>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berney-1999" NAME="Berney 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berney A ,Bryois C</AU>
<TI>Treatment of mania with valproic acic: an open study</TI>
<TO>Traitement de la manie aigue par l'acide valproique: etude overte</TO>
<SO>Schweizer archive fur neurologie und psychiatrie</SO>
<YR>1999</YR>
<VL>150</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brady-1995" NAME="Brady 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brady K, Donne SC, Anton R, Ballenger JC</AU>
<TI>Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>3</NO>
<PG>118-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brennan-1984" NAME="Brennan 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Brennan M, Sandyk R, Borsook D</AU>
<TI>Anticonvulsants in affective disorders</TI>
<SO>Excerpta Medica</SO>
<YR>1984</YR>
<PG>56-65</PG>
<ED>Emrich HM, Okuma T, Muller AA</ED>
<PB>Elsevier Science</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calabrese-1992" NAME="Calabrese 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese JL, Delucchi GA</AU>
<TI>Spectrum of efficacy of valproate in 55 patients with rapid-cycling disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>4</NO>
<PG>431-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calabrese-1992-b" NAME="Calabrese 1992 b" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese JR, Markovitz PL, Kimmel SE, Wagner SC</AU>
<TI>Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1999" NAME="Chen 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen ST, Altshuler LL, Melnyk KA, Erhart SM, Miller E, Mintz J</AU>
<TI>Efficacy of lithium versus valproate in the treatment of mania in the elderly: A retrospective study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>3</NO>
<PG>181-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1996" NAME="Davis 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN et al</AU>
<TI>Valproate as an antidepressant in major depressive disorder</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>4</NO>
<PG>647-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deltito-1998" NAME="Deltito 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Deltito JA, Levitan J, Damore J, Hajal F, Zambenedetti M</AU>
<TI>Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1998</YR>
<VL>97</VL>
<PG>236-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellenor-1995" NAME="Ellenor 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ellenor G, Lohr JB, Ito M, Dishman B, Gammariello A</AU>
<TI>The comparative efficacy of divalproex low and high serum level in bipolar disorder and schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>3</NO>
<PG>563</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emrich-1985" NAME="Emrich 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Emrich HM, Dose M, Von Zerssen D</AU>
<TI>The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1985</YR>
<VL>8</VL>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frankenburg-2002" NAME="Frankenburg 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frankenburg FR, Zanarini MC</AU>
<TI>Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>5</NO>
<PG>442-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1998" NAME="Goldberg 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L</AU>
<TI>Rapid titration of mood stabilisers predicts remission from mixed or pure mania in bipolar patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>4</NO>
<PG>151-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granneman-1996" NAME="Granneman 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Granneman GR, Schneck DW, Cavanaugh JH, Witt GF</AU>
<TI>Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>5</NO>
<PG>204-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayes-1989" NAME="Hayes 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hayes SG</AU>
<TI>Long term use of valproate in primary psychiatric disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>3 Suppl</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobsen-1993" NAME="Jacobsen 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen FM</AU>
<TI>Low dose valproate: A new treatment for cyclothymia, mild rapid cycling disorders and premenstrual syndrome</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>6</NO>
<PG>229-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ketter-1992" NAME="Ketter 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ketter TA, Pazzaglia PJ, Post RN</AU>
<TI>Synergy of carbamazepine and valproic acid in affective illness: A case report and literature review</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>4</NO>
<PG>276-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1984" NAME="Lambert 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Lambert PA</AU>
<TI>Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide)</TI>
<SO>Anticonvulsants in affective disorders</SO>
<YR>1984</YR>
<PG>33-44</PG>
<ED>Emrich HM, Okuma T, Muller AA</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lima-1999" NAME="Lima 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lima WJ, Dopheide JA, Kramer BA, Earhart CA, Wincor MZ</AU>
<TI>A naturalistic comparison of adverse effects between slow titration and loading of divalproex sodium in psychiatric inpatients</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1999</YR>
<VL>52</VL>
<PG>261-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macfarland-1990" NAME="Macfarland 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McFarland BH, Miller MR, Straumfuord AA</AU>
<TI>Valproate use in the older manic patient</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>11</NO>
<PG>479-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElroy-1987" NAME="McElroy 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McElroy SL, Keck PE, Pope HG</AU>
<TI>Sodium valproate: its use in primary psychiatric disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>1</NO>
<PG>16-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElroy-1988" NAME="McElroy 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McElroy SL, Keck PE, Pope HG, Hudson JI</AU>
<TI>Valproate in the treatment of rapid-cycling bipolar disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>4</NO>
<PG>275-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papatheodorou-1993" NAME="Papatheodorou 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Papatheodorou G, Kutcher SP</AU>
<TI>Divalproex sodium treatment in late adolescent and young adult acute mania</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>2</NO>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papatheodorou-1995" NAME="Papatheodorou 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Papatheodorou G, Kutcher SP, Katic M, Szalal JP</AU>
<TI>The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults:an open clinical trial,</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>2</NO>
<PG>110-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puzynski-1984" NAME="Puzynski 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Puzynski S, Klosiewicz L</AU>
<TI>Valproic acid amide in the treatment of affective and schizoaffective disorders</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1984</YR>
<VL>6</VL>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanderson-1998" NAME="Sanderson 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanderson DR</AU>
<TI>Use of mood stabilisers by hospitalised geriatric patients with bipolar disorder</TI>
<SO>Psychiatric Services</SO>
<YR>1998</YR>
<VL>49</VL>
<NO>9</NO>
<PG>1145-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaff-1993" NAME="Schaff 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schaff MR, Fawcett J, Zajecka JM</AU>
<TI>Divalproex sodium in the treatment of refractory affective disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>10</NO>
<PG>380-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1998" NAME="Schneider 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneider AL, Wilcox CS</AU>
<TI>Valproate augmentation in lithium-resistant rapid-cycling mania in four geriatric patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semadeni-1976" NAME="Semadeni 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Semadeni GW</AU>
<TI>A clinical study of the mood stabilising effect of dipropylacetamide</TI>
<TO>Etude clinique de l'effet normothymique du dipropylacetamide</TO>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1976</YR>
<VL>76</VL>
<PG>458-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sommerbeck-1977" NAME="Sommerbeck 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sommerbeck KW, Theilgaard A, Rasmussen KE, Lohren V Gram L, Wulff K</AU>
<TI>Sodium di-n-propylacetate: evalutation of its so-called psychotropic effect</TI>
<TO>Natrium di-n-propylacetat, vurderin af sakaldtd 'psykoatrop effekt' en kontrolleret undersogelse</TO>
<SO>Ugeskr-Laeger</SO>
<YR>1977</YR>
<VL>139</VL>
<NO>18</NO>
<PG>1069-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tariot-2001" NAME="Tariot 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tariot PN, Scheider LS, Mintzer JE, Cutler AJ, Cunningham MR, Thomas JW et al</AU>
<TI>Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial</TI>
<SO>Current Therapeutic Research</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>1</NO>
<PG>51-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-West-1994" NAME="West 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>West SA, Keck PE, McElroy SL, Strakowski SM, Minnery KL, McConville BJ et al</AU>
<TI>Open trial of valproate in the treatment of adolescent mania</TI>
<SO>Journal of Adolescent Psychopharmacology</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>4</NO>
<PG>263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannini-1989" NAME="Giannini 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Giannini AJ, Sullivan BS, Folts DJ</AU>
<TI>Comparison of lithium carbonate, valproic acid and verapamil in the treatment of manic symptoms</TI>
<SO>Abstracts from the Eighteenth Annual Meeting of the American College of Clinical Pharmacology. Journal of Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>29</VL>
<PG>832</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goswami-2001" NAME="Goswami 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goswami U, Ahuja J, Kohli K</AU>
<TI>Comparative efficacy and tolerability of lithium, carbamazepine and valproate in acute mania</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>A19; B4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1987" NAME="Lambert 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert PA, Venaud G</AU>
<TI>Utilisation de valpromide en therapeutique psychiatrique</TI>
<TO>The use of valpromide in psychiatry</TO>
<SO>Encephale</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>367-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morinigo-1992" NAME="Morinigo 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morinigo A, Mateo L, Martin J, Noval D, Gonzalez S</AU>
<TI>The therapeutic effect of sodium valproate and carbamazepine in mania.</TI>
<TO>Efectos terapeuticos del valproato sodico y la carbamacepina en la mania</TO>
<SO>Psiquis</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>8</NO>
<PG>335-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiangin-1995" NAME="Tiangin 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Chinese study - awaiting more details&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tiangin</AU>
<TI>Double-blind placebo controlled study of valproate in treating lithium-resistant mania</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>86-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Battino-1996" NAME="Battino 1996" TYPE="BOOK_SECTION">
<AU>Battino P, Dukes G, Perucca E</AU>
<TI>Anticonvulsants</TI>
<SO>Meyler's side effects of drugs. An encyclopaedia of adverse reactions and interactions</SO>
<YR>1996</YR>
<PG>182-5.</PG>
<EN>14th</EN>
<ED>Dukes MN, Aronson JK</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1989" NAME="Begg 1989" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I et al</AU>
<TI>Improving the quality of reporting of randomised controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhana-2001" NAME="Bhana 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bhana N, Perry CM</AU>
<TI>Olanzapine: A review of its use in the treatment of bipolar I disorder</TI>
<SO>CNS Drugs</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>11</NO>
<PG>871-904</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowden-1996" NAME="Bowden 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bowden CL</AU>
<TI>Role of newer medications for bipolar disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>2 Suppl 1</NO>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>77-188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emrich-1985" NAME="Emrich 1985" TYPE="JOURNAL_ARTICLE">
<AU>Emrich H, Dose M, von Zerssen D</AU>
<TI>The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders</TI>
<SO>Journal of Affective Disorder</SO>
<YR>1985</YR>
<VL>8</VL>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1978" NAME="Endicott 1978" TYPE="JOURNAL_ARTICLE">
<AU>Endicott V, Spitzer RL</AU>
<TI>A diagnostic interview: the schedule for affective disorders and schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>837-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fawcett-1989" NAME="Fawcett 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fawcett J</AU>
<TI>Valproate use in acute mania and bipolar disorder: An international perspective</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>3 Suppl</NO>
<PG>10-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-1995" NAME="FDA 1995" TYPE="BOOK">
<AU>Food and Drug Administration</AU>
<SO>FDA drug and device product approvals</SO>
<YR>1995</YR>
<PB>Center for Drug Evaluation and Research</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilmer-2001" NAME="Gilmer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gilmer WS</AU>
<TI>Anticonvulsants in the treatment of mood disorders: assessing current and future roles</TI>
<SO>Expert Opinion in Pharmacotherapy</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>10</NO>
<PG>1597-608</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-1994" NAME="Goodwin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin G</AU>
<TI>Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>164</VL>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds D, Gavaghan D et al</AU>
<TI>Assessing the quality of reports of randomised clinical trials. Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeavons-1982" NAME="Jeavons 1982" TYPE="JOURNAL_ARTICLE">
<AU>Jeavons PM</AU>
<TI>Sodium valproate and neural tube defects</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>ii</VL>
<PG>1282-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-1999" NAME="Juni 1999" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Witschi A, Bloch R, Egger M</AU>
<TI>The hazards of scoring the quality of clinical trials for meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1054-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keck-1995" NAME="Keck 1995" TYPE="JOURNAL_ARTICLE">
<AU>Keck PE</AU>
<TI>'Lithium: The Present and the Future' . A Symposium Report from the American Psychiatric Association Annual Meeting, 1994</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>1</NO>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lambert-1966" NAME="Lambert 1966" NOTES="&lt;p&gt;Cited by Emrich et al 1985&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lambert PA, Carraz G, Borselli S, Carrel S</AU>
<TI>Neuropsychotropic action of a new antiepileptic: Depramide</TI>
<TO>Action neuropsychotrope d'un novel antiepileptique: le Depamide</TO>
<SO>Annales medico-psychologiques</SO>
<YR>1966</YR>
<VL>1</VL>
<NO>5</NO>
<PG>707-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Licht-1996" NAME="Licht 1996" TYPE="JOURNAL_ARTICLE">
<AU>Licht RW, Gouliaev G, Vestergaard P, Frydenberg G</AU>
<TI>Generalisability of results from randomised controlled trials. A trial of anti-manic treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>170</VL>
<PG>264-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maudsley-2001" NAME="Maudsley 2001" TYPE="BOOK">
<AU>Taylor D, McConnell D, McConnell H, Kerwin R</AU>
<SO>The Maudsley 2001 Prescribing Guidelines</SO>
<YR>2001</YR>
<EN>6th</EN>
<PB>Martin Dunitz</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McElroy-1989" NAME="McElroy 1989" TYPE="JOURNAL_ARTICLE">
<AU>McElroy SL, Keck PE, Pope HG, Hudson JI</AU>
<TI>Valproate in psychiatric disorders: Literature review and clinical guidelines</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>3 Suppl</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McElroy-1992" NAME="McElroy 1992" TYPE="JOURNAL_ARTICLE">
<AU>McElroy SL, Keck PE, Pope HG, Hudson JI, Faedda GL, Swann AC</AU>
<TI>Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<NO>12</NO>
<PG>1633-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-1997" NAME="Moncrieff 1997" TYPE="JOURNAL_ARTICLE">
<AU>Moncrieff J</AU>
<TI>Lithium: Evidence reconsidered</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<NO>8</NO>
<PG>113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ , Lopez AD</AU>
<TI>Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1436-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oxman-1995" NAME="Oxman 1995" TYPE="BOOK_SECTION">
<AU>Oxman A</AU>
<TI>Preparing and maintaining systematic reviews</TI>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1995</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rendell-2001" NAME="Rendell 2001" TYPE="COCHRANE_REVIEW">
<AU>Rendell J</AU>
<TI>Antipsychotic drugs for mania</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sachs-2000" NAME="Sachs 2000" NOTES="&lt;p&gt;. A special report. The expert consensus guideline series &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sachs G, Printz DJ, Kahn DA, Carpenter D, Docherty JP</AU>
<TI>Medication treatment of bipolar disorder 2000</TI>
<SO>Postgraduate medicine</SO>
<YR>2000</YR>
<VL>Spec. No</VL>
<PG>1-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sackett-1997" NAME="Sackett 1997" TYPE="BOOK">
<AU>Sackett D</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1997</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schou-1993" NAME="Schou 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schou M</AU>
<TI>Is there a lithium withdrawal syndrome? An examination of the evidence</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>163</VL>
<PG>514-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JW</AU>
<TI>A rating scale for extra-pyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica Suppl</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spearing-1997" NAME="Spearing 1997" TYPE="JOURNAL_ARTICLE">
<AU>Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W</AU>
<TI>Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP</TI>
<SO>Psychiatry Research</SO>
<YR>1997</YR>
<VL>73</VL>
<PG>159-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1970" NAME="Spitzer 1970" TYPE="BOOK">
<AU>Spitzer RL, Gibbon M, Endicott J</AU>
<TI>Global assessment scale</TI>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<ED>Guy W</ED>
<PB>US Department of Health</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suppes-1991" NAME="Suppes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Suppes T, Baldessarini RJ, Faedda GL,Tohen M</AU>
<TI>Risk of recurrence following discontinuation of lithium treatment in bipolar disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>12</NO>
<PG>1082-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ThiesFlechtner-1996" NAME="ThiesFlechtner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, Walther A, Greil W</AU>
<TI>Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1996</YR>
<VL>29</VL>
<NO>3</NO>
<PG>103-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines</SO>
<YR>1992</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-1978" NAME="Young 1978" TYPE="JOURNAL_ARTICLE">
<AU>Young RC, Biggs JT, Zeigler VE, Meyer DA</AU>
<TI>A rating scale for mania: reliability, validity and sensitivity</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1978</YR>
<VL>133</VL>
<PG>429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bowden-1994">
<CHAR_METHODS>
<P>Multicentre randomised double-blind trial.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>179 hospitalised patients meeting RDC for mania.<BR/>Male and Female.<BR/>Age 18-65y.<BR/>Those with mania scores of at least 14 on last day of wash-out.<BR/>Approximately 50% previously non-responsive to lithium.</P>
<P>Exclusion criteria: <BR/>1. History of severe side effects from lithium.<BR/>2. Prior treatment with divalproex or valproic acid.<BR/>3. Schneiderian first rank symptoms occurring throughout the day without manic symptoms for several days or intermittently for more than one week.<BR/>4.CNS or neuromuscular disorders.<BR/>5. Drug-induced mania or mania induced by HIV.<BR/>substance abuse as defined by SADS.<BR/>6.Positive result on any toxicology screening test for cocaine/phencyclidine/ amphetamines.<BR/>7.Concomitant treatment with any medication that could confound the results.<BR/>8.Pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Divalproex: increased from an initial 750mg/day to a dose allowing a maximum target level of 1041 micromol/L. (150 micrograms per ml) </P>
<P>2.Lithium: starting at a dose of 900mg/day, adjusted to reach a target level of 1.5 mmols per litre. <BR/>3. Placebo adjusted according to blinded protocol specified dosing schedules.</P>
<P>Duration of trial: 21 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response: greater than 50% reduction on Mania Rating scale derived from Schedule for Affective Disorders and Schizophrenia.<BR/>Total numbers of patients withdrawing.<BR/>Numbers withdrawing due to intolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>69 patients randomised to divalproex</P>
<P>36 randomised to lithium</P>
<P>74 randomised to placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Freeman-1992">
<CHAR_METHODS>
<P>Randomised double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>27 patients meeting DSM-III-R criteria for mania.<BR/>21 women and 6 men. Age range not specified.<BR/>Able to give informed consent.</P>
<P>Exclusion criteria:<BR/>1. Abnormal eegs, LFTs, TFTs, haematological findings or positive urine drug screens.<BR/>2. History of drug or alcohol abuse within the previous 12 months or before the onset of major affective episode. 8 patients assigned to valproate and 7 assigned to lithium had previous histories of drug and alcohol abuse during the course of their illness.<BR/>3. Patients with focal neurological abnormalities.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Valproate group: 1500mg/day for first week, 2250 mg/day for second week and 3000 mg/day for third week. </P>
<P>2. Lithium commenced at 0.5 mEq/kg per day increased to maximum or 1800 mg/day or 1.5 mmol/L.</P>
<P>Duration of trial: 21 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response greater than 50% reduction in SAD-C manic factor.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>14 patients randomised to valproate</P>
<P>13 patients randomised to lithium</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hirschfeld-1999">
<CHAR_METHODS>
<P>Randomised double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>59 in-patients meeting DSMIV criteria for bipolar disorder currently manic or mixed. <BR/>Young Mania rating Scale &gt;14 <BR/>Age: 18-60<BR/>Exclusion criteria: <BR/>Intolerance to divalproex or lithium.<BR/>Coexistent medical disorders.<BR/>Substance dependence.<BR/>Serious risk of suicide. Pregnancy.<BR/>Screened positive for amphetamines or phencyclidine.<BR/>Depot antipsychotic drugs.<BR/>Investigational drug within previous 4 weeks.<BR/>Any drug that may interfere with safety or efficacy of trial medications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Divalproex - non-loading: 750mg tds (days 1 and 2) with gradual dose titration (days 3-10).<BR/>Divalproex - loading: 30mg/kg per day (days 1 and 2) then 20mg/kg per day (days 3-10), </P>
<P>2. Lithium: 300mg tds (days 1 and 2); gradual dose titration (days 3-10).</P>
<P>Duration: 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion of patient reaching divalproex levels &gt;50 micrograms per litre.<BR/>Adverse effects.Study withdrawal.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>20 patients randomised to divalproex non-loading</P>
<P>20 patients randomised to divalproex loading</P>
<P>19 randomised to lithium</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kowatch-2000">
<CHAR_METHODS>
<P>Randomised (with minimisation) unblinded trialstratified on age, gender and presence of ADHD.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>42 patients <BR/>Bipolar 1 or 2 (DSM-IV)<BR/>Mixed or manic episode<BR/>Age 6-18 years<BR/>Young Mania Rating scale &gt;14 <BR/>Comorbidity:<BR/>71% with ADHD, <BR/>38% oppositional defiant disorder,<BR/>17% anxiety disorder.</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Divalproex (starting 20mg/kg/day in three divided doses)</P>
<P>2. Lithium (starting 30mg/kg/day in three divided doses)</P>
<P>3. Carbamazepine (starting 15mg/kg/day in three divided doses)<BR/>Duration: 6 weeks</P>
<P>Rescue medication: chlorpromazine 10-50 mg per day up to 3 times per week for weeks 1+2</P>
<P>Serum levels after 1 week - doses adjusted to achieve levels:<BR/>Lithium 0.8-1.2 meq/l<BR/>Carbamazepine 7-10 micrograms/l<BR/>Divalproex 85-110 micrograms/l</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CGI (Bipolar).<BR/>Young Mania Rating Scale (&gt;50% improvement).<BR/>K-SADS for depression and mania.<BR/>Specific adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>15 patients randomised to divalproex</P>
<P>13 patients randomised to lithium</P>
<P>14 patients randomised to carbamazepine</P>
<P>13 randomised to lithium</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McElroy-1996">
<CHAR_METHODS>
<P>Randomised single blinded trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 hospitalised patients with DSM-III-R diagnosed bipolar disorder , manic or mixed episode with psychotic features.<BR/>Age 18-65 y.</P>
<P>Exclusion criteria:<BR/>1. Those unable to provide informed consent.<BR/>2. Prior treatment with valproate.<BR/>3. Unstable medical condition.<BR/>4. History of seizures or neurological disorders.<BR/>5. Psychoactive substance dependence.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Divalproex oral loading dose of 20mg/day adjusted to achieve serum level of 50 micrograms/L.</P>
<P>2.Haloperidol: 0.2mg/kg/day in divided doses.</P>
<P>Duration of trial: 6 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response: greater than or equal to 50% reduction in Y.M.R.S.<BR/>Specific adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>21 patients randomised to divalproex</P>
<P>15 patients randomised to haloperidol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Muller_x002a_-1999">
<CHAR_METHODS>
<P>Multicentre randomised double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>136 hospitalised patients with mania in context of ICD-10 criteria<BR/> for mania. (F25.0,F30.1, F30.2, F30.8, F30.9, F31.1 and F31.2).<BR/>Able to give informed consent.<BR/>Male and Female.<BR/>Age 19-61 y.</P>
<P>Exclusion criteria not listed.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Fixed dose of 20mg/kg sodium valproate</P>
<P>2. Placebo.<BR/>Both groups given neuroleptic medication and benzodiazepines</P>
<P>Duration of trial 21 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response: greater than or equal to 50% reduction in Young Mania Rating Scale.<BR/>Specific adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>69 patients randomised to sodium valproate adjunctive treatment </P>
<P>67 patients randomised to placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pope-1991">
<CHAR_METHODS>
<P>Randomised double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>43 Inpatients<BR/>Bipolar disorder DSM-IIIR criteria<BR/>Previously resistant or intolerant to lithium.<BR/>Males and Females.<BR/>Age 18-65y.</P>
<P>Exclusion criteria:<BR/>1. If subject had previously received more than one 250mg dose of valproate.<BR/>2. Significant medical disorder.<BR/>3. History of neurological disease or focal neurological signs on examination.<BR/>Paroxysmal activity on eeg.<BR/>5. Comorbid psychoactive substance dependence.</P>
<P>Female patients were post-<BR/>menopausal or surgically sterilised.</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Valproate adjusted to achieve serum levels of 50-100mg/litre, dose not stated</P>
<P>2. Placebo.<BR/>Protocol specifies that no other psychotropic medication was allowed during the course of the study except lorazepam.</P>
<P>Duration of trial:<BR/>21 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Young Mania Rating Scale - response defined as 50% reduction .<BR/>Global Assessment Scale.<BR/>Brief Psychiatric Rating Scale, Augmented.<BR/>Total number of subjects withdrawing.<BR/>Number of subjects withdrawing due to intolerance. <BR/>Specific adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>17 patients randomised to valproate</P>
<P>19 patients randomised to placebo</P>
<P>
<BR/>Of 9 responders on valproate, continued as open following response - alone N=2, with lithium (n=4) or neuroleptics (n=3).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tohen-2000">
<CHAR_METHODS>
<P>Randomised double blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>251 participants with DSM-IV bipolar 1 disorder currently hospitalised for an acute manic or mixed episode.<BR/>Young Mania Rating Scale &gt;20.<BR/>Age: 18-75 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Divalproex 500-2500mg per day (initially 750mg) maintained in target range of 50 to 125 micrograms per millilitre</P>
<P>2.Olanzapine 5 - 20mg mg per day (initially 15mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Young Mania Rating Scale - response defined as 50% reduction.<BR/>Hamilton Depression rating Scale.<BR/>Abnormal Involuntary Movement Scale.<BR/>Simpson EPSE scale.<BR/>Barnes Akathisia scale<BR/>Treatment emergent adverse events.<BR/>Total numbers withdrawing. Total numbers withdrawing due to intolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>126 patients randomised to valproate</P>
<P>125 patients randomised to olanzapine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vasudev-2000">
<CHAR_METHODS>
<P>Randomised double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 participants with DSM-IIIR bipolar disorder attending outpatient clinic (hospitalised for study).<BR/>acute manic episode (Young Mania Rating scale &gt;20)<BR/>Age 18-65 years.<BR/>Medication free for 6 months.<BR/>30% drug naive.</P>
<P>Exclusion criteria: seizure disorder cerebrovascular disorder, neurological disorder, general medical disorder.<BR/>Pregnant women or those on the contraceptive pill. Medication for mania prior to inclusion.<BR/>Drug or alcohol dependence.<BR/>Requirement for ECT or antipsychotic medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Carbamazepine 200mg twice daily increased by 200mg to 800mg daily aiming for 20mg/kg/day in 3 divided doses by day 3 (range 800-1200mg day)</P>
<P>2.Sodium valproate initiated 20mg/kg/day (range 800-1400mg daily)<BR/>Further increase in dose, 200-400 mg/day carried out weekly until clinical improvement occurred or serum level not exceeding upper therapeutic range (14 mcg/ml CBZ and 125 mcg/ml valproate).</P>
<P>Maximum doses: CBZ 800-1600 mg/day; Valproate 1000-2200 mg/day by the end of week 4.</P>
<P>Rescue medication: diazepam and promethazine in initial phase of study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Young Mania Rating Scale - response defined as 50% reduction.<BR/>YMRS - mean change baseline to endpoint.<BR/>Number of patients requiring rescue medication.<BR/>Total number of subjects withdrawing.<BR/>Numbers withdrawing due to intolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>15 patients randomised to carbamazepine</P>
<P>15 patients randomised to valproate</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zajecka-2002">
<CHAR_METHODS>
<P>Double-blind randomized controlled trial.<BR/>Trial duration - 12 weeks. Multi-centre trial.Participants who did not meet criteria for improvement after 21 days were discontiunued.<BR/>Washout period 1 - 3 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 participants. Age range 18 - 65</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Divalproex (starting 20mg/kg/day in three divided doses)Divalproex (starting 20mg/kg/day in three divided doses)Divalproex (starting 20mg/kg/day in three divided doses)Olanzapine versus divalproex. </P>
<P>1. Olanzapine starting dose 10mg/day. Dose increased by 500 Divalproex (starting 20mg/kg/day in three divided doses)mg on days 3 abd 6 if clinical symptoms of mania persisted. Mean maximum dose 14.7mg day (range 2 - 25mg/day). </P>
<P>2. Divalproex starting dose 20mg/kg/day. Dose increased by 5 mg on days 3 abd 6 if clinical symptoms of mania persisted. Mean maximum dose 2115mg day (range 750 - 3250mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomeMania Rating Scale (MRS). Secondary outcomes - Manic Syndrome Scale (MSS), Behaviour and Ideation Scale (BIS), Brief Psychiatric Rating Scale (BPRS), Hamilton Depression Scale (HAMD), Clinical Global Improvement Scale (CGI) and Quality of life enjoyment and satisfaction questionnaire (Q-LES-Q)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>63 patients randomised to divalproex</P>
<P>57 patients randomised to olanzapine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Altamura-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Open, uncontrolled trial of lithium and valpromide in the treatment of 59 schizophrenic and 23 manic in-patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berney-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of valproate as a first line treatment of mania in 10 patients with bipolar disorder or schizoaffective disorder, bipolar type.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brady-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of valproate in the acute phase treatment of 9 patients with bipolar affective disorder and concurrent substance abuse.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brennan-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind placebo-controlled trial of sodium valpromide in 8 manic patients using ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calabrese-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open trial of sodium valproate monotherapy or combination therapy with lithium, in acute phase and prophylactic treatment of 55 patients with rapid-cycling bipolar disorder. Non-randomised allocation to monotherapy and combination groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calabrese-1992-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open trial of sodium valproate montherapy or combination therapy with lithium carbonate in the acute phase and prophylactic treatment of 78 patients with rapid-cycling bipolar affective disorder. Non-randomised allocation to monotherapy and combination groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study comparing efficacy of sodium valproate and lithium in the treatment of mania in 59 elderly patients with mania.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised controlled trial studying the effects of valproate in major depressive disorder, but not bipolar depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deltito-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study examining the use of sodium valproate as monotherapy,or in combination, in adolescent patients with various psychiatric conditions, including bipolar affective disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ellenor-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open randomised trial of low-dose versus high-dose valproate in the acute phase treatment of patients with bipolar disorder and schizophrenia. Allocation by unspecified randomisation process. No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emrich-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>An ABA design trial examining the antimanic efficacy of valproate. The comparator phase involved placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frankenburg-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double blind placebo-controlled trial examining efficacy and safety of valproate in the treatment of female patients with borderline personality disorder and co-morbid bipolar (II) disorder. Patients are not suffering from an acute affective episode.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldberg-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study examining time to remission for 120 bipolar patients with pure or mixed mania treated with lithium, carbamazepine or valproate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Granneman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised cross-over trial examining pharmacokinetic interactions and side-effects resulting from concomitant administration of lithium and divalproex sodium in healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayes-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study of valproate treatment in acute, continuation and prophylactic phases either alone or in combination with lithium in 35 patients with major depressive illness, bipolar affective disorder or schizoaffective disorder previously refractory to lithium and/or carbamazepine treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobsen-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of sodium valproate treatment in out-patients with cyclothymia, rapid-cycling bipolar affective disorder (bipolar II) and premenstrual syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ketter-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report of carbamazepine and sodium valproate combination therapy in a patient with rapid-cycling disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lambert-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of sodium valproate in 141 patients with bipolar affective disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lima-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised naturalistic comparison of the incidence severity and onset of treatment emergent adverse effects, comparing slow titration and loading of divalproex sodium in 47 psychiatric patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Macfarland-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series of 7 elderly manic patients given acute phase sodium valproate adjunctive treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McElroy-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective case note review of sodium valproate in hospitalised patients with various psychiatric diagnoses including acute affective episodes in bipolar disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McElroy-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective case series describing effect of sodium valproate in combination with lithium or neuroleptics in 6 patients with rapid-cycling bipolar affective disorder refractory to lithium and neuroleptics, and some refractory to carbamazepine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papatheodorou-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Preliminary report on open, uncontrolled trial of divalproex sodium in acute phase treatemtn in 15 bipolar adolescents and young adults.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papatheodorou-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of divalproex sodium in the acute phase treatment of acute mania in 15 adolescents with mania.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Puzynski-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of valproate in 10 bipolar patients and 5 schizoaffective patients (12 refractory to lithium).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanderson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case note review of 72 patients with bipolar disorder aged over 60 treated with lithium, carbamazepine or valproate monotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schaff-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case note review of adjunctive sodium valproate in the acute and maintenance treatment phase in 63 patients with bipolar I, bipolar II and schizoaffective disorder (bipolar type), previously refractory to lithium, carbamazepine or combination treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series of four geriatric patients with rapid-cycling bipolar disorder treated with combination of valproate and lithium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Semadeni-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open trial of sodium valproate in 32 patients, 16 of whom were refractory to lithium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sommerbeck-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study examining the psychotropic effect of sodium dipropylacetate in patients with epilepsy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tariot-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial - but participants had mania with dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-West-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, uncontrolled trial of valproate in the acute phase treatment of 11 adolescents with mania refractory to lithium/antipsychotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Giannini-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Goswami-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lambert-1987">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Morinigo-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Tiangin-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Freeman-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hirschfeld-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kowatch-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McElroy-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002a_-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pope-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tohen-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vasudev-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zajecka-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Valproate v. placebo</NAME>
<DICH_OUTCOME CHI2="0.8400959095787389" CI_END="0.7599284459787438" CI_START="0.5249945046933354" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6316314258323336" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.11922729848178994" LOG_CI_START="-0.2798452424870933" LOG_EFFECT_SIZE="-0.1995362704844416" METHOD="MH" NO="1" P_CHI2="0.8398545854600699" P_Q="0.8295015337478463" P_Z="1.1174454807454628E-6" Q="0.04637179737398191" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="227" WEIGHT="200.0" Z="4.8697411261351355">
<NAME>Clinical response - categorical outcomes</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8293912495058616" CI_END="0.7653447338273214" CI_START="0.5086532416409599" DF="2" EFFECT_SIZE="0.6239351567543735" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="111" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.11614290174099952" LOG_CI_START="-0.29357818340392994" LOG_EFFECT_SIZE="-0.20486054257246475" NO="1" P_CHI2="0.6605413175502173" P_Z="6.01642980664115E-6" STUDIES="3" TAU2="0.0" TOTAL_1="155" TOTAL_2="161" WEIGHT="100.0" Z="4.525811118649132">
<NAME>Failure to respond by end of study - &lt;50% reduction on YMRS or SADS-C mania scale.</NAME>
<DICH_DATA CI_END="0.8908835404271099" CI_START="0.5238629320711415" EFFECT_SIZE="0.6831550802139037" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="55" LOG_CI_END="-0.05017906482460856" LOG_CI_START="-0.2807823306348888" LOG_EFFECT_SIZE="-0.16548069772974866" ORDER="30659" O_E="0.0" SE="0.13545749984153432" STUDY_ID="STD-Bowden-1994" TOTAL_1="68" TOTAL_2="73" VAR="0.018348734263319275" WEIGHT="48.95326499441006"/>
<DICH_DATA CI_END="0.8396602313040018" CI_START="0.35668896301608854" EFFECT_SIZE="0.5472636815920398" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="36" LOG_CI_END="-0.07589641574858935" LOG_CI_START="-0.4477103287759384" LOG_EFFECT_SIZE="-0.26180337226226386" ORDER="30660" O_E="0.0" SE="0.21840533302081766" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.04770088949193427" WEIGHT="33.46993244839151"/>
<DICH_DATA CI_END="0.9188236251793833" CI_START="0.3983626345355893" EFFECT_SIZE="0.605" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" LOG_CI_END="-0.036767846571122725" LOG_CI_START="-0.3997214041239396" LOG_EFFECT_SIZE="-0.2182446253475311" ORDER="30661" O_E="0.0" SE="0.21320071635561047" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.04545454545454547" WEIGHT="17.57680255719842"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.99840219522952" CI_START="0.43196665193027234" DF="0" EFFECT_SIZE="0.6567164179104478" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-6.944727587877153E-4" LOG_CI_START="-0.3645497796704903" LOG_EFFECT_SIZE="-0.182622126214639" NO="2" P_CHI2="1.0" P_Z="0.049131843402796006" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="66" WEIGHT="100.0" Z="1.9674457585838139">
<NAME>Failure to respond by end of trial - CGI change score of 3+</NAME>
<DICH_DATA CI_END="0.99840219522952" CI_START="0.43196665193027234" EFFECT_SIZE="0.6567164179104478" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" LOG_CI_END="-6.944727587877153E-4" LOG_CI_START="-0.3645497796704903" LOG_EFFECT_SIZE="-0.182622126214639" ORDER="30662" O_E="0.0" SE="0.2137304083927513" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.04568068747173225" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.839763063077637" CI_END="13.001562470817404" CI_START="2.5432187854365376" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="7.7723906281269715" ESTIMABLE="YES" I2="73.95672640284" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.05005064235909851" P_Q="1.0" P_Z="0.0035774927512969685" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="85" UNITS="" WEIGHT="100.0" Z="2.913196613762028">
<NAME>Clinical response -general health and social functioning.</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.839763063077637" CI_END="13.001562470817404" CI_START="2.5432187854365376" DF="1" EFFECT_SIZE="7.7723906281269715" ESTIMABLE="YES" I2="73.95672640284" ID="CMP-001.02.01" NO="1" P_CHI2="0.05005064235909851" P_Z="0.0035774927512969685" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="85" WEIGHT="100.0" Z="2.913196613762028">
<NAME>Global Assessment Scale</NAME>
<CONT_DATA CI_END="10.97273903828772" CI_START="-0.7727390382877317" EFFECT_SIZE="5.099999999999994" ESTIMABLE="YES" MEAN_1="64.6" MEAN_2="59.5" ORDER="30663" SD_1="16.4" SD_2="18.1" SE="2.996350486341148" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="67" TOTAL_2="66" WEIGHT="79.28379358041103"/>
<CONT_DATA CI_END="29.488882798987397" CI_START="6.511117201012603" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="50.6" MEAN_2="32.6" ORDER="30664" SD_1="19.9" SD_2="14.5" SE="5.861782609073553" STUDY_ID="STD-Pope-1991" TOTAL_1="17" TOTAL_2="19" WEIGHT="20.716206419588968"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.81673146359167" CI_END="1.2252767447951338" CI_START="0.6195488547650835" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8712742415612403" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" I2="20.60549843322084" I2_Q="74.69904247711001" ID="CMP-001.03" LOG_CI_END="0.08823419087467378" LOG_CI_START="-0.2079244414778821" LOG_EFFECT_SIZE="-0.05984512530160417" METHOD="MH" NO="3" P_CHI2="0.2660833330278426" P_Q="0.019208212704389993" P_Z="0.42829976313155815" Q="7.904839167413263" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="405" TOTAL_2="422" WEIGHT="300.0" Z="0.7921044833959145">
<NAME>Withdrawal from trial</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6457364406470747" CI_END="0.9241442604985892" CI_START="0.4287477664190283" DF="2" EFFECT_SIZE="0.6294638889862824" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="46" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.034260229377043386" LOG_CI_START="-0.36779812942011797" LOG_EFFECT_SIZE="-0.20102917939858064" NO="1" P_CHI2="0.7240693204383606" P_Z="0.018146766177612312" STUDIES="3" TAU2="0.0" TOTAL_1="158" TOTAL_2="163" WEIGHT="99.99999999999999" Z="2.362609774853025">
<NAME>Withdrawal due to lack of treatment response</NAME>
<DICH_DATA CI_END="0.9020672596037953" CI_START="0.38940160190268414" EFFECT_SIZE="0.5926773455377574" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" LOG_CI_END="-0.044761079547009544" LOG_CI_START="-0.4096022662313305" LOG_EFFECT_SIZE="-0.22718167288917002" ORDER="30665" O_E="0.0" SE="0.21430951905137088" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.045928569956029903" WEIGHT="82.56514033610276"/>
<DICH_DATA CI_END="5.229100334783306" CI_START="0.04507798114265141" EFFECT_SIZE="0.4855072463768116" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7184269750529637" LOG_CI_START="-1.3460355424537838" LOG_EFFECT_SIZE="-0.3138042837004101" ORDER="30666" O_E="0.0" SE="1.2126755020377393" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="1.4705818732424831" WEIGHT="4.56920087773324"/>
<DICH_DATA CI_END="2.5439023378109074" CI_START="0.3303105489894152" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4055004344276508" LOG_CI_START="-0.4810775562064505" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="30667" O_E="0.0" SE="0.5207803003303036" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.27121212121212124" WEIGHT="12.86565878616399"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04779478776541175" CI_END="5.507702791982751" CI_START="0.6610322128387454" DF="2" EFFECT_SIZE="1.908079915580711" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.7409704967111721" LOG_CI_START="-0.17977737634304766" LOG_EFFECT_SIZE="0.28059656018406226" NO="2" P_CHI2="0.9763859011151896" P_Z="0.2322463871096515" STUDIES="3" TAU2="0.0" TOTAL_1="158" TOTAL_2="163" WEIGHT="100.00000000000001" Z="1.1945922836016205">
<NAME>Withdrawal due to adverse events</NAME>
<DICH_DATA CI_END="11.341758629453283" CI_START="0.4056438058678342" EFFECT_SIZE="2.1449275362318843" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0546804005754467" LOG_CI_START="-0.39185515126004244" LOG_EFFECT_SIZE="0.3314126246577021" ORDER="30668" O_E="0.0" SE="0.8497021436146305" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.7219937328632982" WEIGHT="39.79904977809643"/>
<DICH_DATA CI_END="20.916401339133223" CI_START="0.1803119245706056" EFFECT_SIZE="1.9420289855072463" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.320486966380926" LOG_CI_START="-0.7439755511258216" LOG_EFFECT_SIZE="0.2882557076275523" ORDER="30669" O_E="0.0" SE="1.2126755020377393" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="1.4705818732424831" WEIGHT="20.923765140690403"/>
<DICH_DATA CI_END="8.885154292442541" CI_START="0.3064099857349331" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9486649738154436" LOG_CI_START="-0.5136970853876313" LOG_EFFECT_SIZE="0.21748394421390627" ORDER="30670" O_E="0.0" SE="0.8589987123848253" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.7378787878787878" WEIGHT="39.27718508121318"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1904511313683592" CI_END="13.173338274763118" CI_START="0.7988554093795326" DF="1" EFFECT_SIZE="3.24400871459695" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="15.99823179213127" ID="CMP-001.03.03" LOG_CI_END="1.119695844103465" LOG_CI_START="-0.09753181967363508" LOG_EFFECT_SIZE="0.5110820122149149" NO="3" P_CHI2="0.27523863656092984" P_Z="0.09978948123707485" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="96" WEIGHT="99.99999999999999" Z="1.6458750764490118">
<NAME>Withdawal because patient no longer needed hospital admission</NAME>
<DICH_DATA CI_END="9.339901543604661" CI_START="0.27708019075375295" EFFECT_SIZE="1.608695652173913" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9703422981471624" LOG_CI_START="-0.5573945220483583" LOG_EFFECT_SIZE="0.20647388804940212" ORDER="30671" O_E="0.0" SE="0.8974001706020739" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.8053270661966314" WEIGHT="80.17429193899781"/>
<DICH_DATA CI_END="172.3323478821665" CI_START="0.5638132741773969" EFFECT_SIZE="9.857142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2363668049474277" LOG_CI_START="-0.2488647035014304" LOG_EFFECT_SIZE="0.9937510507229985" ORDER="30672" O_E="0.0" SE="1.4598372901572316" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.1311249137336095" WEIGHT="19.825708061002178"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.785378223430243" CI_END="1.4982080204305819" CI_START="0.984147225900724" CI_STUDY="95" CI_TOTAL="95" DF="35" EFFECT_MEASURE="RR" EFFECT_SIZE="1.214272320004443" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="136" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.17557211767119532" LOG_CI_START="-0.006939927367993516" LOG_EFFECT_SIZE="0.08431609515160089" METHOD="MH" NO="4" P_CHI2="0.7178292563265771" P_Q="0.48976429402216204" P_Z="0.07015467228362646" Q="24.515635439295366" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1751" TOTAL_2="1818" WEIGHT="2600.0" Z="1.810910724042419">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1461813849284654" CI_END="2.4545519711555266" CI_START="0.36860452293270973" DF="1" EFFECT_SIZE="0.951188182402055" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="53.40561580570549" ID="CMP-001.04.01" LOG_CI_END="0.3899722320142593" LOG_CI_START="-0.43343934010808305" LOG_EFFECT_SIZE="-0.021733554046911893" NO="1" P_CHI2="0.14292504551333618" P_Z="0.9175942269899264" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="96" WEIGHT="99.99999999999999" Z="0.10346462116923712">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="4.509550451369011" CI_START="0.4999056892248884" EFFECT_SIZE="1.5014492753623188" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6541332500329844" LOG_CI_START="-0.30111192068906667" LOG_EFFECT_SIZE="0.1765106646719589" ORDER="30673" O_E="0.0" SE="0.5611157418219889" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.3148508757204409" WEIGHT="59.08798972382787"/>
<DICH_DATA CI_END="2.8536510799567147" CI_START="0.008578673366015468" EFFECT_SIZE="0.1564625850340136" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4554008702105867" LOG_CI_START="-2.066579867671753" LOG_EFFECT_SIZE="-0.8055894987305832" ORDER="30674" O_E="0.0" SE="1.4814239694380784" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.1946169772256727" WEIGHT="40.91201027617212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.021080593023301675" CI_END="1.3957741780603186" CI_START="0.2985050541263475" DF="1" EFFECT_SIZE="0.6454809420657233" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.14481515957977192" LOG_CI_START="-0.5250483112327651" LOG_EFFECT_SIZE="-0.19011657582649655" NO="2" P_CHI2="0.8845596290400366" P_Z="0.2659103079962428" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="96" WEIGHT="99.99999999999999" Z="1.112530113134922">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="1.4945439451561486" CI_START="0.2914404561141899" EFFECT_SIZE="0.6599777034559643" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.17450868943768286" LOG_CI_START="-0.5354501620800275" LOG_EFFECT_SIZE="-0.18047073632117233" ORDER="30675" O_E="0.0" SE="0.41703334373449685" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.173916809786375" WEIGHT="86.81845416417015"/>
<DICH_DATA CI_END="5.612438628376065" CI_START="0.053898139477300114" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.749151605057554" LOG_CI_START="-1.2684262260690662" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="30676" O_E="0.0" SE="1.1851352051751118" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="1.4045454545454545" WEIGHT="13.181545835829837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.36399266877263214" CI_END="2.5609670594074405" CI_START="0.8244720539975225" DF="2" EFFECT_SIZE="1.4530814745531813" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.40840399236550734" LOG_CI_START="-0.08382406045652374" LOG_EFFECT_SIZE="0.16228996595449177" NO="3" P_CHI2="0.8336044392740763" P_Z="0.19621201784654035" STUDIES="3" TAU2="0.0" TOTAL_1="158" TOTAL_2="165" WEIGHT="100.0" Z="1.292419180497381">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="3.122767419601871" CI_START="0.7792561048975467" EFFECT_SIZE="1.5599472990777339" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.49453963964329134" LOG_CI_START="-0.10831978666045008" LOG_EFFECT_SIZE="0.1931099264914206" ORDER="30677" O_E="0.0" SE="0.3541226112131065" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.12540282377238898" WEIGHT="64.81771415790651"/>
<DICH_DATA CI_END="21.54830308633774" CI_START="0.18562946622632753" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3334130754593223" LOG_CI_START="-0.7313530841313599" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="30678" O_E="0.0" SE="1.212853862900895" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="69" VAR="1.471014492753623" WEIGHT="6.106016551107135"/>
<DICH_DATA CI_END="3.244394675876169" CI_START="0.37295092640763017" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5111336800425463" LOG_CI_START="-0.4283483097260961" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="30679" O_E="0.0" SE="0.5518563713009523" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.30454545454545456" WEIGHT="29.07626929098636"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9361017028393066" CI_END="6.6147639905800215" CI_START="0.8523714664302889" DF="1" EFFECT_SIZE="2.374497016789232" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="48.34982074890523" ID="CMP-001.04.04" LOG_CI_END="0.8205143535246887" LOG_CI_START="-0.06937109694385862" LOG_EFFECT_SIZE="0.375571628290415" NO="4" P_CHI2="0.1640927019476358" P_Z="0.0980491778064729" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="96" WEIGHT="99.99999999999999" Z="1.6543856620572885">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="12.45034558302107" CI_START="1.0264583744120503" EFFECT_SIZE="3.57487922705314" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0951814062683918" LOG_CI_START="0.011341342279725155" LOG_EFFECT_SIZE="0.5532613742740584" ORDER="30680" O_E="0.0" SE="0.6366530186817867" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.4053270661966314" WEIGHT="60.31635909532398"/>
<DICH_DATA CI_END="5.612438628376065" CI_START="0.053898139477300114" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.749151605057554" LOG_CI_START="-1.2684262260690662" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="30681" O_E="0.0" SE="1.1851352051751118" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="1.4045454545454545" WEIGHT="39.683640904676004"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.64767159700938" CI_START="0.2617381579913048" DF="0" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="2.0399994137307593" LOG_CI_START="-0.5821329583038349" LOG_EFFECT_SIZE="0.728933227713462" NO="5" P_CHI2="1.0" P_Z="0.275840610710517" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="74" WEIGHT="100.0" Z="1.0897107168883013">
<NAME>Twitching</NAME>
<DICH_DATA CI_END="109.64767159700938" CI_START="0.2617381579913048" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0399994137307593" LOG_CI_START="-0.5821329583038349" LOG_EFFECT_SIZE="0.728933227713462" ORDER="30682" O_E="0.0" SE="1.540253535097697" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="2.3723809523809525" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1681818186754396" CI_START="0.38460493275139046" DF="0" EFFECT_SIZE="0.6702898550724637" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.06751044269260173" LOG_CI_START="-0.4149851500170096" LOG_EFFECT_SIZE="-0.1737373536622039" NO="6" P_CHI2="1.0" P_Z="0.15810005529929233" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="75" WEIGHT="100.0" Z="1.4114904305547025">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.1681818186754396" CI_START="0.38460493275139046" EFFECT_SIZE="0.6702898550724637" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" LOG_CI_END="0.06751044269260173" LOG_CI_START="-0.4149851500170096" LOG_EFFECT_SIZE="-0.1737373536622039" ORDER="30683" O_E="0.0" SE="0.28342029954932907" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.08032706619663142" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30684" O_E="0.0" SE="0.0" STUDY_ID="STD-Pope-1991" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4002565545553611" CI_END="3.0784876692524747" CI_START="0.8147274064091181" DF="2" EFFECT_SIZE="1.5837071302587862" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="0.4883374183834587" LOG_CI_START="-0.08898767432142451" LOG_EFFECT_SIZE="0.19967487203101708" NO="7" P_CHI2="0.49652166670597253" P_Z="0.1751772797938767" STUDIES="3" TAU2="0.0" TOTAL_1="158" TOTAL_2="163" WEIGHT="100.00000000000001" Z="1.3557545401841409">
<NAME>Sedation</NAME>
<DICH_DATA CI_END="2.6377015630485268" CI_START="0.6090331548145368" EFFECT_SIZE="1.2674571805006587" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.4212256566943735" LOG_CI_START="-0.21535906440970842" LOG_EFFECT_SIZE="0.10293329614233258" ORDER="30685" O_E="0.0" SE="0.37393301632172826" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.1398259006954659" WEIGHT="87.91200094963006"/>
<DICH_DATA CI_END="70.30104949768797" CI_START="0.12080987816219027" EFFECT_SIZE="2.914285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469618084857198" LOG_CI_START="-0.9178975536624361" LOG_EFFECT_SIZE="0.4645321274116419" ORDER="30686" O_E="0.0" SE="1.6240920756003987" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="2.637675070028011" WEIGHT="4.200793996227859"/>
<DICH_DATA CI_END="36.1465485656329" CI_START="0.5355974710793533" EFFECT_SIZE="4.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5580668352277638" LOG_CI_START="-0.27116148225538883" LOG_EFFECT_SIZE="0.6434526764861874" ORDER="30687" O_E="0.0" SE="1.0744977685158097" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="1.1545454545454545" WEIGHT="7.887205054142102"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.32862590851101" CI_START="0.14143996749380947" DF="0" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.08" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" NO="8" P_CHI2="1.0" P_Z="0.45854828508739953" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.7412394307675078">
<NAME>Anorexia</NAME>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380947" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" ORDER="30688" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09347268641569961" CI_END="8.884769672920857" CI_START="1.1316412967306508" DF="1" EFFECT_SIZE="3.170863017195369" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="0.0" ID="CMP-001.04.09" LOG_CI_END="0.9486461737197031" LOG_CI_START="0.053708787684732646" LOG_EFFECT_SIZE="0.5011774807022178" NO="9" P_CHI2="0.7598079404023226" P_Z="0.028148206802481947" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="141" WEIGHT="100.00000000000001" Z="2.195214609126814">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="8.827912854138303" CI_START="0.9853093598112969" EFFECT_SIZE="2.949275362318841" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.945858037317703" LOG_CI_START="-0.006427391669735869" LOG_EFFECT_SIZE="0.46971532282398354" ORDER="30689" O_E="0.0" SE="0.5593771748761197" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.312902823772389" WEIGHT="88.38558466572299"/>
<DICH_DATA CI_END="99.32709805431861" CI_START="0.23751662131307125" EFFECT_SIZE="4.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9970677472868268" LOG_CI_START="-0.62430599323083" LOG_EFFECT_SIZE="0.6863808770279982" ORDER="30690" O_E="0.0" SE="1.5398079111893614" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="2.3710084033613446" WEIGHT="11.614415334277032"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1688293099350941" CI_END="3.336656499215853" CI_START="0.7235860490308652" DF="1" EFFECT_SIZE="1.5538204829518618" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-001.04.10" LOG_CI_END="0.5233114993806819" LOG_CI_START="-0.14050981506722682" LOG_EFFECT_SIZE="0.1914008421567275" NO="10" P_CHI2="0.6811546025503066" P_Z="0.25837505666572447" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="141" WEIGHT="99.99999999999997" Z="1.1302401687713794">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="3.5006578024921784" CI_START="0.5431309322243617" EFFECT_SIZE="1.3788819875776397" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5441496595360013" LOG_CI_START="-0.26509546269842343" LOG_EFFECT_SIZE="0.1395270984187889" ORDER="30691" O_E="0.0" SE="0.4753545906284613" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.22596198683155203" WEIGHT="68.93555394641562"/>
<DICH_DATA CI_END="7.450256101831148" CI_START="0.506221065289734" EFFECT_SIZE="1.9420289855072463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8721712018355949" LOG_CI_START="-0.2956597865804903" LOG_EFFECT_SIZE="0.2882557076275523" ORDER="30692" O_E="0.0" SE="0.6859897034522335" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="0.47058187324248324" WEIGHT="31.064446053584355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7771228263864284E-32" CI_END="3.355574549061662" CI_START="0.038085166343837386" DF="0" EFFECT_SIZE="0.35748792270531393" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.0" ID="CMP-001.04.11" LOG_CI_END="0.5257668917550423" LOG_CI_START="-1.4192441432069256" LOG_EFFECT_SIZE="-0.44673862572594164" NO="11" P_CHI2="0.0" P_Z="0.36793606854162664" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="74" WEIGHT="100.0" Z="0.9003461689284303">
<NAME>Fever</NAME>
<DICH_DATA CI_END="3.3555745490616613" CI_START="0.03808516634383742" EFFECT_SIZE="0.357487922705314" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5257668917550422" LOG_CI_START="-1.4192441432069252" LOG_EFFECT_SIZE="-0.4467386257259416" ORDER="30693" O_E="0.0" SE="1.1425091098965605" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="1.3053270661966312" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.32862590851101" CI_START="0.14143996749380947" DF="0" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.12" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" NO="12" P_CHI2="1.0" P_Z="0.45854828508739953" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.7412394307675078">
<NAME>Agitation</NAME>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380947" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" ORDER="30694" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.61816341755203" CI_START="0.27865799953456794" DF="0" EFFECT_SIZE="5.476190476190476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.04.13" LOG_CI_END="2.031885576221638" LOG_CI_START="-0.5549284849822533" LOG_EFFECT_SIZE="0.7384785456196924" NO="13" P_CHI2="1.0" P_Z="0.2631174367492456" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.119053258970231">
<NAME>Ataxia</NAME>
<DICH_DATA CI_END="107.61816341755203" CI_START="0.27865799953456794" EFFECT_SIZE="5.476190476190476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.031885576221638" LOG_CI_START="-0.5549284849822533" LOG_EFFECT_SIZE="0.7384785456196924" ORDER="30695" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.308902691511387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.447340105237235" CI_START="0.07356812665500279" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.04.14" LOG_CI_END="1.216095673044557" LOG_CI_START="-1.1333103027281068" LOG_EFFECT_SIZE="0.04139268515822508" NO="14" P_CHI2="1.0" P_Z="0.9449397030015587" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.06906271029369085">
<NAME>Diplopia</NAME>
<DICH_DATA CI_END="16.447340105237227" CI_START="0.07356812665500283" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2160956730445567" LOG_CI_START="-1.1333103027281066" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="30696" O_E="0.0" SE="1.3800526999160048" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="1.9045454545454545" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.32862590851101" CI_START="0.14143996749380947" DF="0" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.15" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" NO="15" P_CHI2="1.0" P_Z="0.45854828508739953" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.7412394307675078">
<NAME>Dysarthria</NAME>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380947" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" ORDER="30697" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18182184420746583" CI_END="1.6787157779847872" CI_START="0.4669232516177103" DF="1" EFFECT_SIZE="0.885342549298638" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" ID="CMP-001.04.16" LOG_CI_END="0.22497717231334244" LOG_CI_START="-0.3307544987446411" LOG_EFFECT_SIZE="-0.05288866321564929" NO="16" P_CHI2="0.6698122348638358" P_Z="0.7091058074873136" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="96" WEIGHT="100.0" Z="0.37305728822615686">
<NAME>Pain</NAME>
<DICH_DATA CI_END="1.8097665737622681" CI_START="0.47736094207659363" EFFECT_SIZE="0.9294685990338164" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.25762256256836175" LOG_CI_START="-0.3211531180786089" LOG_EFFECT_SIZE="-0.03176527775512361" ORDER="30698" O_E="0.0" SE="0.33997569979785563" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.11558347645304165" WEIGHT="88.37162024801789"/>
<DICH_DATA CI_END="5.612438628376065" CI_START="0.053898139477300114" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.749151605057554" LOG_CI_START="-1.2684262260690662" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="30699" O_E="0.0" SE="1.1851352051751118" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="1.4045454545454545" WEIGHT="11.628379751982111"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.304726536702083" CI_START="0.011146319981382718" DF="0" EFFECT_SIZE="0.21904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.04.17" LOG_CI_END="0.6339455675496006" LOG_CI_START="-1.9528684936542908" LOG_EFFECT_SIZE="-0.6594614630523452" NO="17" P_CHI2="1.0" P_Z="0.3176422582292885" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.9993147448511664">
<NAME>Dysuria</NAME>
<DICH_DATA CI_END="4.304726536702083" CI_START="0.011146319981382718" EFFECT_SIZE="0.21904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6339455675496006" LOG_CI_START="-1.9528684936542908" LOG_EFFECT_SIZE="-0.6594614630523452" ORDER="30700" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.308902691511387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.447340105237235" CI_START="0.07356812665500279" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.04.18" LOG_CI_END="1.216095673044557" LOG_CI_START="-1.1333103027281068" LOG_EFFECT_SIZE="0.04139268515822508" NO="18" P_CHI2="1.0" P_Z="0.9449397030015587" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.06906271029369085">
<NAME>Palpitations</NAME>
<DICH_DATA CI_END="16.447340105237227" CI_START="0.07356812665500283" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2160956730445567" LOG_CI_START="-1.1333103027281066" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="30701" O_E="0.0" SE="1.3800526999160048" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="1.9045454545454545" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.32862590851101" CI_START="0.14143996749380947" DF="0" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.19" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" NO="19" P_CHI2="1.0" P_Z="0.45854828508739953" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.7412394307675078">
<NAME>Chest tightness</NAME>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380947" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" ORDER="30702" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1162780921111897" CI_START="0.02784573624362897" DF="0" EFFECT_SIZE="0.2427536231884058" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.04.20" LOG_CI_END="0.32557273611068305" LOG_CI_START="-1.5552412948394656" LOG_EFFECT_SIZE="-0.6148342793643913" NO="20" P_CHI2="1.0" P_Z="0.20004741998759037" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="1.2814164762542495">
<NAME>Tremor</NAME>
<DICH_DATA CI_END="2.1162780921111897" CI_START="0.02784573624362897" EFFECT_SIZE="0.2427536231884058" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32557273611068305" LOG_CI_START="-1.5552412948394656" LOG_EFFECT_SIZE="-0.6148342793643913" ORDER="30703" O_E="0.0" SE="1.1047994719597232" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="1.2205818732424831" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.25217384784137" CI_START="0.36787091562482654" DF="0" EFFECT_SIZE="1.9420289855072463" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.04.21" LOG_CI_END="1.0108159619794372" LOG_CI_START="-0.43430454672433255" LOG_EFFECT_SIZE="0.2882557076275523" NO="21" P_CHI2="1.0" P_Z="0.43427258522227763" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="0.7819013042654448">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="10.25217384784137" CI_START="0.36787091562482654" EFFECT_SIZE="1.9420289855072463" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0108159619794372" LOG_CI_START="-0.43430454672433255" LOG_EFFECT_SIZE="0.2882557076275523" ORDER="30704" O_E="0.0" SE="0.8488709402744821" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="0.7205818732424832" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.25217384784137" CI_START="0.36787091562482654" DF="0" EFFECT_SIZE="1.9420289855072463" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.04.22" LOG_CI_END="1.0108159619794372" LOG_CI_START="-0.43430454672433255" LOG_EFFECT_SIZE="0.2882557076275523" NO="22" P_CHI2="1.0" P_Z="0.43427258522227763" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="0.7819013042654448">
<NAME>Hypersalivation</NAME>
<DICH_DATA CI_END="10.25217384784137" CI_START="0.36787091562482654" EFFECT_SIZE="1.9420289855072463" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0108159619794372" LOG_CI_START="-0.43430454672433255" LOG_EFFECT_SIZE="0.2882557076275523" ORDER="30705" O_E="0.0" SE="0.8488709402744821" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="0.7205818732424832" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.61910228293709" CI_START="0.3599970689499886" DF="0" EFFECT_SIZE="0.9710144927536232" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.04.23" LOG_CI_END="0.41815245911548876" LOG_CI_START="-0.4437010351883465" LOG_EFFECT_SIZE="-0.01277428803642889" NO="23" P_CHI2="1.0" P_Z="0.9536684189946174" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="0.05810069726471397">
<NAME>Extra-pyramidal side-effects</NAME>
<DICH_DATA CI_END="2.61910228293709" CI_START="0.3599970689499886" EFFECT_SIZE="0.9710144927536232" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41815245911548876" LOG_CI_START="-0.4437010351883465" LOG_EFFECT_SIZE="-0.01277428803642889" ORDER="30706" O_E="0.0" SE="0.5062570087976748" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="0.25629615895676894" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.695968722479616" CI_START="0.14081146197296124" DF="0" EFFECT_SIZE="0.9710144927536232" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.04.24" LOG_CI_END="0.8258134163582269" LOG_CI_START="-0.8513619924310847" LOG_EFFECT_SIZE="-0.01277428803642889" NO="24" P_CHI2="1.0" P_Z="0.9761816403442263" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="0.02985632194263433">
<NAME>Dyskinesia</NAME>
<DICH_DATA CI_END="6.695968722479616" CI_START="0.14081146197296124" EFFECT_SIZE="0.9710144927536232" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8258134163582269" LOG_CI_START="-0.8513619924310847" LOG_EFFECT_SIZE="-0.01277428803642889" ORDER="30707" O_E="0.0" SE="0.9851811372750106" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="0.9705818732424832" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="25" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Dystonia</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30708" O_E="0.0" SE="0.0" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.32709805431861" CI_START="0.23751662131307114" DF="0" EFFECT_SIZE="4.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.04.26" LOG_CI_END="1.9970677472868268" LOG_CI_START="-0.6243059932308302" LOG_EFFECT_SIZE="0.6863808770279982" NO="26" P_CHI2="1.0" P_Z="0.30470568248941066" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="1.0263945028962047">
<NAME>Blood dyscrasio</NAME>
<DICH_DATA CI_END="99.32709805431861" CI_START="0.23751662131307125" EFFECT_SIZE="4.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9970677472868268" LOG_CI_START="-0.62430599323083" LOG_EFFECT_SIZE="0.6863808770279982" ORDER="30709" O_E="0.0" SE="1.5398079111893614" STUDY_ID="STD-Muller_x002a_-1999" TOTAL_1="69" TOTAL_2="67" VAR="2.3710084033613446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.32862590851101" CI_START="0.14143996749380947" DF="0" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.27" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" NO="27" P_CHI2="1.0" P_Z="0.45854828508739953" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.7412394307675078">
<NAME>Dry eyes</NAME>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380947" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419524" LOG_EFFECT_SIZE="0.516629796003336" ORDER="30710" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Pope-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Valproate v. lithium</NAME>
<DICH_OUTCOME CHI2="3.0939454254152468" CI_END="1.4538949783110957" CI_START="0.7791286866855145" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0643172858833914" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="33" I2="3.036428006891495" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.16253303651802825" LOG_CI_START="-0.10839080509800385" LOG_EFFECT_SIZE="0.02707111571001222" METHOD="MH" NO="1" P_CHI2="0.37736648948053053" P_Q="0.880331423752723" P_Z="0.6952909243762309" Q="0.022665033560685645" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="112" TOTAL_2="74" WEIGHT="200.0" Z="0.3916850691061561">
<NAME>Clinical response - categorical outcomes</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Lithium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lithium</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.01886717950008" CI_END="1.4995211369643817" CI_START="0.7389169670334865" DF="2" EFFECT_SIZE="1.0526260544601422" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="26" I2="33.749983650118814" ID="CMP-002.01.01" LOG_CI_END="0.17595259187100273" LOG_CI_START="-0.13140436104386422" LOG_EFFECT_SIZE="0.02227411541356926" NO="1" P_CHI2="0.22103521202023002" P_Z="0.7763516549012274" STUDIES="3" TAU2="0.0" TOTAL_1="97" TOTAL_2="61" WEIGHT="100.0" Z="0.2840766319685399">
<NAME>Failure to respond clinically - &lt;50% reduction on YMRS or SADS-C mania subscale.</NAME>
<DICH_DATA CI_END="1.5201524725179965" CI_START="0.6566911297095224" EFFECT_SIZE="0.9991349480968859" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.1818871502159822" LOG_CI_START="-0.18263884992867646" LOG_EFFECT_SIZE="-3.758498563471156E-4" ORDER="30711" O_E="0.0" SE="0.21412437691777472" STUDY_ID="STD-Bowden-1994" TOTAL_1="68" TOTAL_2="35" VAR="0.04584924879042526" WEIGHT="70.02512756083178"/>
<DICH_DATA CI_END="34.64908063329537" CI_START="0.6221268228475204" EFFECT_SIZE="4.642857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5396917156813394" LOG_CI_START="-0.2061210737521042" LOG_EFFECT_SIZE="0.6667853209646176" ORDER="30712" O_E="0.0" SE="1.0254990744258874" STUDY_ID="STD-Freeman-1992" TOTAL_1="14" TOTAL_2="13" VAR="1.0516483516483517" WEIGHT="3.2351734570908435"/>
<DICH_DATA CI_END="1.5132899620939289" CI_START="0.38001272647624307" EFFECT_SIZE="0.7583333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.17992215133576886" LOG_CI_START="-0.4202018587888313" LOG_EFFECT_SIZE="-0.12013985372653124" ORDER="30713" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="26.739698982077382"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1369456523440165" CI_START="0.5810314603458807" DF="0" EFFECT_SIZE="1.1142857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.32979347715366486" LOG_CI_START="-0.2358003518012177" LOG_EFFECT_SIZE="0.04699656267622358" NO="2" P_CHI2="1.0" P_Z="0.7446389961099367" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.325716319828961">
<NAME>Failure to respond by end of trial - CGI change score of 3+</NAME>
<DICH_DATA CI_END="2.1369456523440165" CI_START="0.5810314603458807" EFFECT_SIZE="1.1142857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.32979347715366486" LOG_CI_START="-0.2358003518012177" LOG_EFFECT_SIZE="0.04699656267622358" ORDER="30714" O_E="0.0" SE="0.33223261486270483" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.11037851037851037" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.179620096359102" CI_START="-22.77962009635911" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.300000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.17629894110357988" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="99.99999999999999" Z="1.3522387816512627">
<NAME>Clinical response -general health and social functioning.</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Lithium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lithium</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.179620096359102" CI_START="-22.77962009635911" DF="0" EFFECT_SIZE="-9.300000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.17629894110357988" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="99.99999999999999" Z="1.3522387816512627">
<NAME>Score on Global Assessment Scale</NAME>
<CONT_DATA CI_END="4.179620096359102" CI_START="-22.77962009635911" EFFECT_SIZE="-9.300000000000004" ESTIMABLE="YES" MEAN_1="61.9" MEAN_2="71.2" ORDER="30715" SD_1="20.8" SD_2="14.6" SE="6.877483567394416" STUDY_ID="STD-Freeman-1992" TOTAL_1="14" TOTAL_2="13" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.23704834955343446" CI_END="1.5861810215255943" CI_START="0.5662749693941657" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9477418474553143" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.20035274928894461" LOG_CI_START="-0.24697263472565606" LOG_EFFECT_SIZE="-0.023309942718355743" METHOD="MH" NO="3" P_CHI2="0.8882303461058924" P_Q="0.8169229818332807" P_Z="0.8381457610916772" Q="0.05359427965854715" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="158" TOTAL_2="91" WEIGHT="200.0" Z="0.20426584245967014">
<NAME>Withdrawal from trial</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Lithium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lithium</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.18963486937597446" CI_END="1.6611353546186534" CI_START="0.5673207857166712" DF="1" EFFECT_SIZE="0.9707711442786069" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.22040502159586872" LOG_CI_START="-0.24617130429589873" LOG_EFFECT_SIZE="-0.012883141350014986" NO="1" P_CHI2="0.66322069398" P_Z="0.9138074162402827" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.10823735218672671">
<NAME>Withdrawal due to lack of treatment response</NAME>
<DICH_DATA CI_END="1.6367223181813793" CI_START="0.5093401513098468" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.21397500445107423" LOG_CI_START="-0.2929920870184215" LOG_EFFECT_SIZE="-0.039508541283673634" ORDER="30716" O_E="0.0" SE="0.29779497905675767" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.08868184955141475" WEIGHT="83.67537313432837"/>
<DICH_DATA CI_END="4.92972849971403" CI_START="0.3254630441691702" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6928230015646754" LOG_CI_START="-0.48749831777037983" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="30717" O_E="0.0" SE="0.6933265856621718" STUDY_ID="STD-Hirschfeld-1999" TOTAL_1="20" TOTAL_2="19" VAR="0.4807017543859648" WEIGHT="16.324626865671643"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4346106777902768E-32" CI_END="4.473195596804274" CI_START="0.13692143731607906" DF="0" EFFECT_SIZE="0.7826086956521741" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="100.0" ID="CMP-002.03.03" LOG_CI_END="0.6506178887283336" LOG_CI_START="-0.863528550556907" LOG_EFFECT_SIZE="-0.10645533091428673" NO="3" P_CHI2="0.0" P_Z="0.7828560859520894" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="0.27559898982133973">
<NAME>Withdawal because patient no longer needed hospital admission</NAME>
<DICH_DATA CI_END="4.473195596804272" CI_START="0.13692143731607906" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6506178887283335" LOG_CI_START="-0.863528550556907" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="30718" O_E="0.0" SE="0.8894171135819049" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.7910628019323671" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.152546523886375" CI_END="0.987112854959964" CI_START="0.5922730972128585" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7646178051195022" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="82" I2="6.719390163328556" I2_Q="17.706816313820834" ID="CMP-002.04" LOG_CI_END="-0.0056331923308549645" LOG_CI_START="-0.22747799384454376" LOG_EFFECT_SIZE="-0.11655559308769937" METHOD="MH" NO="4" P_CHI2="0.3757930426771213" P_Q="0.2602560637030368" P_Z="0.03944629574855844" Q="15.797177138722489" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="933" TOTAL_2="530" WEIGHT="1400.0" Z="2.059500723838241">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Lithium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lithium</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6766483652496789" CI_START="0.2209827681549975" DF="0" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.22444198983062608" LOG_CI_START="-0.6556415905093357" LOG_EFFECT_SIZE="-0.21559980033935483" NO="1" P_CHI2="1.0" P_Z="0.3369091642565871" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="0.9602902569229413">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="1.6766483652496789" CI_START="0.2209827681549975" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.22444198983062608" LOG_CI_START="-0.6556415905093357" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="30719" O_E="0.0" SE="0.5169654515756767" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.26725327812284333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.34552860296986154" CI_END="1.956880344914776" CI_START="0.2762051081080862" DF="1" EFFECT_SIZE="0.7351872871736661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.2915642711705457" LOG_CI_START="-0.5587682938868552" LOG_EFFECT_SIZE="-0.1336020113581548" NO="2" P_CHI2="0.556655451179585" P_Z="0.5379679500702095" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.6158887505535399">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="2.3668837435042933" CI_START="0.2944217288631921" EFFECT_SIZE="0.8347826086956521" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.37417692679493725" LOG_CI_START="-0.5310301414230238" LOG_EFFECT_SIZE="-0.0784266073140433" ORDER="30720" O_E="0.0" SE="0.5317231127184842" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.2827294685990338" WEIGHT="80.93076049943245"/>
<DICH_DATA CI_END="7.092090538223847" CI_START="0.013769741019755389" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8507742712041247" LOG_CI_START="-1.8610742278439367" LOG_EFFECT_SIZE="-0.5051499783199059" ORDER="30721" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="19.069239500567537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06708144623776141" CI_END="1.4305808109443272" CI_START="0.4359490885285298" DF="1" EFFECT_SIZE="0.789721723518851" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.15551239535060135" LOG_CI_START="-0.360564226011563" LOG_EFFECT_SIZE="-0.10252591533048082" NO="3" P_CHI2="0.7956345801258726" P_Z="0.43612753485537037" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.7787490973698957">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.4586449718597947" CI_START="0.3948315200063507" EFFECT_SIZE="0.758893280632411" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.16394959927871633" LOG_CI_START="-0.403588184223253" LOG_EFFECT_SIZE="-0.11981929247226834" ORDER="30722" O_E="0.0" SE="0.33337450338639385" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.11113855950812472" WEIGHT="82.32719928186714"/>
<DICH_DATA CI_END="3.880477204887019" CI_START="0.2244855632740339" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5888851366007625" LOG_CI_START="-0.6488115833556488" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="30723" O_E="0.0" SE="0.7270291799999699" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="0.5285714285714286" WEIGHT="17.67280071813285"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2970939919567697" CI_START="0.25908982249229756" DF="0" EFFECT_SIZE="0.5797101449275363" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="0.11297144771796289" LOG_CI_START="-0.5865496465365487" LOG_EFFECT_SIZE="-0.2367890994092929" NO="4" P_CHI2="1.0" P_Z="0.1845409728648958" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.00000000000001" Z="1.3269023924674752">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="1.2970939919567697" CI_START="0.25908982249229756" EFFECT_SIZE="0.5797101449275363" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.11297144771796289" LOG_CI_START="-0.5865496465365487" LOG_EFFECT_SIZE="-0.2367890994092929" ORDER="30724" O_E="0.0" SE="0.41090215345036213" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.16884057971014493" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.98808693191301" CI_START="0.060853972140479586" DF="0" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.04.05" LOG_CI_END="0.298435370616971" LOG_CI_START="-1.2157110686682695" LOG_EFFECT_SIZE="-0.4586378490256493" NO="5" P_CHI2="1.0" P_Z="0.23508816757010909" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="1.187353670311476">
<NAME>Twitching</NAME>
<DICH_DATA CI_END="1.98808693191301" CI_START="0.060853972140479586" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.298435370616971" LOG_CI_START="-1.2157110686682695" LOG_EFFECT_SIZE="-0.4586378490256493" ORDER="30725" O_E="0.0" SE="0.8894171135819049" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.7910628019323671" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.025441498743776" CI_START="0.3047350282983212" DF="0" EFFECT_SIZE="0.5590062111801242" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-002.04.06" LOG_CI_END="0.010910888987686298" LOG_CI_START="-0.5160776221727361" LOG_EFFECT_SIZE="-0.2525833665925249" NO="6" P_CHI2="1.0" P_Z="0.0602711361372522" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="1.878804911800155">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.0254414987437763" CI_START="0.3047350282983212" EFFECT_SIZE="0.5590062111801242" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.010910888987686393" LOG_CI_START="-0.5160776221727361" LOG_EFFECT_SIZE="-0.2525833665925249" ORDER="30726" O_E="0.0" SE="0.30955566009083396" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.09582470669427193" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.658506940701869" CI_END="2.727615426721112" CI_START="0.58767627623313" DF="1" EFFECT_SIZE="1.2660785429709733" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="39.704804637307895" ID="CMP-002.04.07" LOG_CI_END="0.4357831380421758" LOG_CI_START="-0.23086184086463904" LOG_EFFECT_SIZE="0.10246064858876833" NO="7" P_CHI2="0.19780510489693304" P_Z="0.5468565767967752" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="50" WEIGHT="100.0" Z="0.602477142769185">
<NAME>Sedation</NAME>
<DICH_DATA CI_END="2.21271812761674" CI_START="0.4242983577543905" EFFECT_SIZE="0.968944099378882" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.344926093810935" LOG_CI_START="-0.37232864916571123" LOG_EFFECT_SIZE="-0.01370127767738809" ORDER="30727" O_E="0.0" SE="0.4213189864927209" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.17750968837925357" WEIGHT="94.68791500664011"/>
<DICH_DATA CI_END="116.70106774092213" CI_START="0.3690318099368892" EFFECT_SIZE="6.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0670748295832384" LOG_CI_START="-0.43293619675521183" LOG_EFFECT_SIZE="0.8170693164140133" ORDER="30728" O_E="0.0" SE="1.4685188521253716" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="2.1565476190476187" WEIGHT="5.312084993359894"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30729" O_E="0.0" SE="0.0" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.423923725674861" CI_START="0.5697040478686529" DF="0" EFFECT_SIZE="1.9130434782608696" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-002.04.09" LOG_CI_END="0.807800375714713" LOG_CI_START="-0.24435069477752389" LOG_EFFECT_SIZE="0.2817248404685946" NO="9" P_CHI2="1.0" P_Z="0.2939006218069711" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="50" WEIGHT="100.0" Z="1.0496031536809842">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="6.423923725674858" CI_START="0.569704047868653" EFFECT_SIZE="1.9130434782608696" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.8078003757147129" LOG_CI_START="-0.2443506947775238" LOG_EFFECT_SIZE="0.2817248404685946" ORDER="30730" O_E="0.0" SE="0.618038747038936" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.381971892841458" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30731" O_E="0.0" SE="0.0" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6528787401843847" CI_START="0.27224177347000167" DF="0" EFFECT_SIZE="0.6708074534161491" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-002.04.10" LOG_CI_END="0.21824099368004748" LOG_CI_START="-0.5650452347698475" LOG_EFFECT_SIZE="-0.17340212054489998" NO="10" P_CHI2="1.0" P_Z="0.3855122042425674" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="0.8677847222807827">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="1.6528787401843847" CI_START="0.2722417734700017" EFFECT_SIZE="0.6708074534161491" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.21824099368004748" LOG_CI_START="-0.5650452347698474" LOG_EFFECT_SIZE="-0.17340212054489998" ORDER="30732" O_E="0.0" SE="0.46010620792083184" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.21169772256728775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8597216449772068" CI_START="0.012665109541777799" DF="0" EFFECT_SIZE="0.10434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.04.11" LOG_CI_END="-0.06564213901046312" LOG_CI_START="-1.8973910496015105" LOG_EFFECT_SIZE="-0.9815165943059869" NO="11" P_CHI2="1.0" P_Z="0.03569036126846693" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="2.1004376352514567">
<NAME>Fever</NAME>
<DICH_DATA CI_END="0.8597216449772068" CI_START="0.012665109541777799" EFFECT_SIZE="0.10434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.06564213901046312" LOG_CI_START="-1.8973910496015105" LOG_EFFECT_SIZE="-0.9815165943059869" ORDER="30733" O_E="0.0" SE="1.0759783773845244" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="1.1577294685990338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.09209053822385" CI_START="0.013769741019755389" DF="0" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.04.12" LOG_CI_END="0.850774271204125" LOG_CI_START="-1.8610742278439367" LOG_EFFECT_SIZE="-0.5051499783199059" NO="12" P_CHI2="1.0" P_Z="0.4652770182299425" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="99.99999999999999" Z="0.7301851594185668">
<NAME>Polyuria</NAME>
<DICH_DATA CI_END="7.092090538223847" CI_START="0.013769741019755389" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8507742712041247" LOG_CI_START="-1.8610742278439367" LOG_EFFECT_SIZE="-0.5051499783199059" ORDER="30734" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5950181600868567" CI_START="0.009779157833002605" DF="0" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.04.13" LOG_CI_END="0.5557010885452137" LOG_CI_START="-2.0096985444177387" LOG_EFFECT_SIZE="-0.7269987279362623" NO="13" P_CHI2="1.0" P_Z="0.2666315176694517" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.1108532996208509">
<NAME>Increased appetite</NAME>
<DICH_DATA CI_END="3.595018160086855" CI_START="0.009779157833002613" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5557010885452135" LOG_CI_START="-2.009698544417738" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="30735" O_E="0.0" SE="1.5069284433354269" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="2.270833333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="49.79902699407837" CI_START="0.9237887463907042" DF="0" EFFECT_SIZE="6.782608695652174" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-002.04.16" LOG_CI_END="1.6972208573133152" LOG_CI_START="-0.03442733263957776" LOG_EFFECT_SIZE="0.8313967623368688" NO="16" P_CHI2="1.0" P_Z="0.059831818681435785" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="1.8820309119345981">
<NAME>Pain</NAME>
<DICH_DATA CI_END="49.79902699407837" CI_START="0.9237887463907042" EFFECT_SIZE="6.782608695652174" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.6972208573133152" LOG_CI_START="-0.03442733263957776" LOG_EFFECT_SIZE="0.8313967623368688" ORDER="30736" O_E="0.0" SE="1.0171787185751138" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="1.0346525455221107" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9648971913165934" CI_START="0.13853738578782623" DF="0" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.04.21" LOG_CI_END="0.2933398318554868" LOG_CI_START="-0.8584330117954229" LOG_EFFECT_SIZE="-0.28254658996996806" NO="21" P_CHI2="1.0" P_Z="0.33624294223185147" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="36" WEIGHT="100.0" Z="0.9616152062421586">
<NAME>Drop-out from study due to intolerance</NAME>
<DICH_DATA CI_END="1.9648971913165934" CI_START="0.13853738578782623" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.2933398318554868" LOG_CI_START="-0.8584330117954229" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="30737" O_E="0.0" SE="0.676557069728071" STUDY_ID="STD-Bowden-1994" TOTAL_1="69" TOTAL_2="36" VAR="0.4577294685990338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Valproate v. carbamazepine</NAME>
<DICH_OUTCOME CHI2="0.5866565047769662" CI_END="1.1012533029820777" CI_START="0.4926224306765564" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7365474043845497" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.04188722399875492" LOG_CI_START="-0.3074858172284033" LOG_EFFECT_SIZE="-0.13279929661482417" METHOD="MH" NO="1" P_CHI2="0.7457773260303443" P_Q="0.497073244103336" P_Z="0.13622585729632172" Q="0.46117957534680254" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="42" WEIGHT="200.0" Z="1.4899938336574465">
<NAME>Clinical response - categorical outcomes</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Carbamaze</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.158551696543334" CI_END="1.1600234342157776" CI_START="0.37507674966136306" DF="1" EFFECT_SIZE="0.6596194503171248" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.06446676271640155" LOG_CI_START="-0.425879856155139" LOG_EFFECT_SIZE="-0.18070654671936875" NO="1" P_CHI2="0.6904936488065767" P_Z="0.14856917171624573" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="1.4446039177578338">
<NAME>Failure to respond clinically - &lt;50% reduction on YMRS</NAME>
<DICH_DATA CI_END="1.4146284322310363" CI_START="0.3725136848128532" EFFECT_SIZE="0.725925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.15064238260049115" LOG_CI_START="-0.42885776820551363" LOG_EFFECT_SIZE="-0.13910769280251123" ORDER="30738" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="14" VAR="0.11587301587301588" WEIGHT="57.08245243128964"/>
<DICH_DATA CI_END="1.5509351337896784" CI_START="0.2105378910638429" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19059363428922826" LOG_CI_START="-0.6766697316618172" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="30739" O_E="0.0" SE="0.5094347941825426" STUDY_ID="STD-Vasudev-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.25952380952380955" WEIGHT="42.91754756871036"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4492804727533324E-31" CI_END="1.501556339678948" CI_START="0.5002217307888084" DF="0" EFFECT_SIZE="0.8666666666666668" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="100.0" ID="CMP-003.01.02" LOG_CI_END="0.17654163194135566" LOG_CI_START="-0.30083744543904456" LOG_EFFECT_SIZE="-0.0621479067488444" NO="2" P_CHI2="0.0" P_Z="0.6098284293394146" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.510318380984369">
<NAME>Failure to respond clinically - CGI change score of 3+</NAME>
<DICH_DATA CI_END="1.5015563396789477" CI_START="0.5002217307888084" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.17654163194135558" LOG_CI_START="-0.30083744543904456" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="30740" O_E="0.0" SE="0.2804148331177911" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.07863247863247863" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.1843664851249125" CI_START="0.23898480296955818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Withdrawal from trial</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours carbam</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal from trial due to adverse effects</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30741" O_E="0.0" SE="0.0" STUDY_ID="STD-Vasudev-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.1843664851249125" CI_START="0.23898480296955818" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Total trial withdrawal</NAME>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="30742" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Vasudev-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.163200576643879" CI_END="2.395289457355552" CI_START="0.20228251793709892" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.696078431372549" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.37935800298494404" LOG_CI_START="-0.6940416490706286" LOG_EFFECT_SIZE="-0.1573418230428423" METHOD="MH" NO="3" P_CHI2="0.5590032782490832" P_Q="0.5650075352636295" P_Z="0.5655661574364738" Q="1.1418330198774091" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="76" TOTAL_2="66" WEIGHT="300.0" Z="0.5745936396295375">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Carbamazepin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Constipation</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.620229879332466" CI_START="0.2552781445363355" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.8208730700427579" LOG_CI_START="-0.5929863654290843" LOG_EFFECT_SIZE="0.11394335230683679" NO="2" P_CHI2="1.0" P_Z="0.7520722181157173" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.3159081605939555">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="6.620229879332466" CI_START="0.2552781445363355" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8208730700427579" LOG_CI_START="-0.5929863654290843" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="30743" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30744" O_E="0.0" SE="0.0" STUDY_ID="STD-Kowatch-2000" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Twitching</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Sedation</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.599912503353394" CI_START="0.012889480641026817" DF="0" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.03.08" LOG_CI_END="0.8195381780323705" LOG_CI_START="-1.8897645814270692" LOG_EFFECT_SIZE="-0.5351132016973492" NO="8" P_CHI2="1.0" P_Z="0.4387987840002805" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.774223256752582">
<NAME>Rash</NAME>
<DICH_DATA CI_END="6.599912503353391" CI_START="0.012889480641026829" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8195381780323703" LOG_CI_START="-1.8897645814270687" LOG_EFFECT_SIZE="-0.5351132016973492" ORDER="30745" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="2.532738095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.599912503353394" CI_START="0.012889480641026817" DF="0" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.03.09" LOG_CI_END="0.8195381780323705" LOG_CI_START="-1.8897645814270692" LOG_EFFECT_SIZE="-0.5351132016973492" NO="9" P_CHI2="1.0" P_Z="0.4387987840002805" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.774223256752582">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="6.599912503353391" CI_START="0.012889480641026829" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8195381780323703" LOG_CI_START="-1.8897645814270687" LOG_EFFECT_SIZE="-0.5351132016973492" ORDER="30746" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="2.532738095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Asthenia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Fever</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Polyuria</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30747" O_E="0.0" SE="0.0" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Increased appetite</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30748" O_E="0.0" SE="0.0" STUDY_ID="STD-Kowatch-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="16" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Valproate v. olanzapine</NAME>
<DICH_OUTCOME CHI2="0.008250567208399005" CI_END="1.4727273975330166" CI_START="1.0709381506333782" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2558662171987576" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="123" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.16812236618853427" LOG_CI_START="0.029764389959532036" LOG_EFFECT_SIZE="0.09894337807403317" METHOD="MH" NO="1" P_CHI2="0.9276255802647133" P_Q="0.9278867797975585" P_Z="0.005059166364794093" Q="0.008190959446262757" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="246" TOTAL_2="250" WEIGHT="200.0" Z="2.8032421811787813">
<NAME>Clinical response - categorical outcomes</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6156834283506223" CI_START="0.9917918123181168" DF="0" EFFECT_SIZE="1.2658679218371132" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="57" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.2083562705544208" LOG_CI_START="-0.0035794813239359603" LOG_EFFECT_SIZE="0.10238839461524239" NO="1" P_CHI2="1.0" P_Z="0.05825707230834258" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="125" WEIGHT="100.0" Z="1.8937585008869235">
<NAME>Failure to respond clinically &lt;50% improvement on YMRS.</NAME>
<DICH_DATA CI_END="1.6156834283506223" CI_START="0.9917918123181168" EFFECT_SIZE="1.2658679218371132" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="57" LOG_CI_END="0.2083562705544208" LOG_CI_START="-0.0035794813239359603" LOG_EFFECT_SIZE="0.10238839461524239" ORDER="30749" O_E="0.0" SE="0.12449210975223819" STUDY_ID="STD-Tohen-2000" TOTAL_1="123" TOTAL_2="125" VAR="0.015498285390563318" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5370863049144088" CI_START="1.0120307690811365" DF="0" EFFECT_SIZE="1.247228381374723" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="66" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.1866982531183524" LOG_CI_START="0.0051937166925268355" LOG_EFFECT_SIZE="0.09594598490543958" NO="2" P_CHI2="1.0" P_Z="0.038253137072597546" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="125" WEIGHT="100.0" Z="2.072131954153497">
<NAME>Failure to remit by end of trial</NAME>
<DICH_DATA CI_END="1.5370863049144088" CI_START="1.0120307690811365" EFFECT_SIZE="1.247228381374723" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="66" LOG_CI_END="0.1866982531183524" LOG_CI_START="0.0051937166925268355" LOG_EFFECT_SIZE="0.09594598490543958" ORDER="30750" O_E="0.0" SE="0.10661666315847547" STUDY_ID="STD-Tohen-2000" TOTAL_1="123" TOTAL_2="125" VAR="0.01136711286304782" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8925637892728838" CI_END="1.3045583933964024" CI_START="0.864651216671188" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0620677954202404" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.11546352334598295" LOG_CI_START="-0.06315904308077093" LOG_EFFECT_SIZE="0.026152240132605996" METHOD="MH" NO="3" P_CHI2="0.8272220705387168" P_Q="0.6596575399366384" P_Z="0.5660225692351135" Q="0.832068961685327" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="441" TOTAL_2="432" WEIGHT="300.0" Z="0.5739190719328224">
<NAME>Withdrawal from trial</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3604855221783607" CI_START="0.4961976652806332" DF="0" EFFECT_SIZE="1.0822510822510822" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.37300134107003574" LOG_CI_START="-0.3043452835102491" LOG_EFFECT_SIZE="0.0343280287798933" NO="1" P_CHI2="1.0" P_Z="0.8425267296384249" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="125" WEIGHT="99.99999999999999" Z="0.1986625388752359">
<NAME>Withdrawal from trial due to failure to respond</NAME>
<DICH_DATA CI_END="2.3604855221783607" CI_START="0.4961976652806332" EFFECT_SIZE="1.0822510822510822" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.37300134107003574" LOG_CI_START="-0.3043452835102491" LOG_EFFECT_SIZE="0.0343280287798933" ORDER="30751" O_E="0.0" SE="0.39787676019832613" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.1583059163059163" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.90498802753809E-32" CI_END="1.7030801305991687" CI_START="0.3250621326993369" DF="0" EFFECT_SIZE="0.7440476190476192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="100.0" ID="CMP-004.03.02" LOG_CI_END="0.23123508217185193" LOG_CI_START="-0.48803361960746466" LOG_EFFECT_SIZE="-0.12839926871780635" NO="2" P_CHI2="0.0" P_Z="0.48407684094768566" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0" Z="0.6997605810057719">
<NAME>Withdrawal from trial due to adverse events</NAME>
<DICH_DATA CI_END="1.7030801305991683" CI_START="0.3250621326993369" EFFECT_SIZE="0.7440476190476191" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.23123508217185182" LOG_CI_START="-0.48803361960746466" LOG_EFFECT_SIZE="-0.12839926871780644" ORDER="30752" O_E="0.0" SE="0.4225019958626663" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.17850793650793648" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10712493941483267" CI_END="1.3707761355219699" CI_START="0.8951347825737195" DF="1" EFFECT_SIZE="1.107713590251425" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="77" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.13696653498941733" LOG_CI_START="-0.048111567007104686" LOG_EFFECT_SIZE="0.04442748399115632" NO="3" P_CHI2="0.7434414323084332" P_Z="0.3467213647195674" STUDIES="2" TAU2="0.0" TOTAL_1="189" TOTAL_2="182" WEIGHT="100.0" Z="0.940967814204541">
<NAME>Withdrawal from treatment</NAME>
<DICH_DATA CI_END="1.6247275206072476" CI_START="0.8064811340115616" EFFECT_SIZE="1.1446886446886446" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.21078053687236584" LOG_CI_START="-0.09340578759368998" LOG_EFFECT_SIZE="0.05868737463933796" ORDER="30753" O_E="0.0" SE="0.17868055273795166" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.031926739926739924" WEIGHT="49.529050693195046"/>
<DICH_DATA CI_END="1.3634329943666326" CI_START="0.8419623028168985" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.13463379948932652" LOG_CI_START="-0.07470735273444007" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="30754" O_E="0.0" SE="0.12296802907165649" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" VAR="0.015121136173767757" WEIGHT="50.470949306804954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="45.59220135558558" CI_END="0.682510351608772" CI_START="0.4496641773354823" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5539859707421383" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="196" I2="80.25978186530931" I2_Q="84.13681067855077" ID="CMP-004.04" LOG_CI_END="-0.16589075730921998" LOG_CI_START="-0.34711170928598534" LOG_EFFECT_SIZE="-0.2565012332976026" METHOD="MH" NO="4" P_CHI2="7.167905147209552E-7" P_Q="2.0191655658585717E-7" P_Z="2.8847744090006236E-8" Q="44.1273180200594" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="945" TOTAL_2="910" WEIGHT="800.0" Z="5.548289795076934">
<NAME>Adverse events (dichotomous)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Extra-pyramidal side effects</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6684722340597128" CI_START="0.0588918983999144" DF="0" EFFECT_SIZE="0.1984126984126984" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="-0.17491662706330352" LOG_CI_START="-1.2299444458277473" LOG_EFFECT_SIZE="-0.7024305364455253" NO="2" P_CHI2="1.0" P_Z="0.009057873090883288" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0" Z="2.609862088161231">
<NAME>Increased appetite</NAME>
<DICH_DATA CI_END="0.6684722340597127" CI_START="0.058891898399914426" EFFECT_SIZE="0.1984126984126984" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.17491662706330358" LOG_CI_START="-1.229944445827747" LOG_EFFECT_SIZE="-0.7024305364455253" ORDER="30755" O_E="0.0" SE="0.6197285632141639" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.384063492063492" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.926063859195773" CI_START="1.532135569700055" DF="0" EFFECT_SIZE="2.7472527472527473" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="13" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.6925000375308106" LOG_CI_START="0.18529719517107748" LOG_EFFECT_SIZE="0.438898616350944" NO="3" P_CHI2="1.0" P_Z="6.937499434603844E-4" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0" Z="3.392037303695546">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="4.926063859195774" CI_START="1.532135569700055" EFFECT_SIZE="2.7472527472527473" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="13" LOG_CI_END="0.6925000375308106" LOG_CI_START="0.18529719517107748" LOG_EFFECT_SIZE="0.438898616350944" ORDER="30756" O_E="0.0" SE="0.2979334602966689" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.08876434676434677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9032945624278627" CI_START="0.0031460730356349456" DF="0" EFFECT_SIZE="0.05330882352941176" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="-0.044170604086942775" LOG_CI_START="-2.5022311995115047" LOG_EFFECT_SIZE="-1.2732009017992238" NO="4" P_CHI2="1.0" P_Z="0.04231550032571086" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="57" WEIGHT="100.0" Z="2.030403902373595">
<NAME>Oedema</NAME>
<DICH_DATA CI_END="0.9032945624278627" CI_START="0.0031460730356349456" EFFECT_SIZE="0.05330882352941176" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.044170604086942775" LOG_CI_START="-2.5022311995115047" LOG_EFFECT_SIZE="-1.2732009017992238" ORDER="30757" O_E="0.0" SE="1.4438769613485716" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" VAR="2.0847806795131847" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6294830838010146" CI_START="0.1962360488269499" DF="0" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="0.2120498562709342" LOG_CI_START="-0.7072212091449644" LOG_EFFECT_SIZE="-0.2475856764370151" NO="5" P_CHI2="1.0" P_Z="0.2910836604397278" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="57" WEIGHT="100.0" Z="1.0557473788974197">
<NAME>Rhinitis</NAME>
<DICH_DATA CI_END="1.6294830838010146" CI_START="0.1962360488269499" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2120498562709342" LOG_CI_START="-0.7072212091449644" LOG_EFFECT_SIZE="-0.2475856764370151" ORDER="30758" O_E="0.0" SE="0.5399843742904616" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" VAR="0.29158312447786133" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1826492997046883" CI_END="0.7559406417675733" CI_START="0.4066930293327534" DF="1" EFFECT_SIZE="0.5544689257264108" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="76" I2="0.0" ID="CMP-004.04.07" LOG_CI_END="-0.12151230498144412" LOG_CI_START="-0.3907332712842843" LOG_EFFECT_SIZE="-0.2561227881328642" NO="7" P_CHI2="0.6691062971125987" P_Z="1.9207717326363987E-4" STUDIES="2" TAU2="0.0" TOTAL_1="189" TOTAL_2="182" WEIGHT="100.00000000000001" Z="3.7292150552325007">
<NAME>Sedation</NAME>
<DICH_DATA CI_END="0.7901116698679987" CI_START="0.35070745301766887" EFFECT_SIZE="0.5264010366051183" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="49" LOG_CI_END="-0.10231152367143463" LOG_CI_START="-0.45505500466296966" LOG_EFFECT_SIZE="-0.2786832641672021" ORDER="30759" O_E="0.0" SE="0.20720326684281945" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.042933193790336645" WEIGHT="63.44068619517722"/>
<DICH_DATA CI_END="0.971643256798241" CI_START="0.3744374279030128" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" LOG_CI_END="-0.012493158985678715" LOG_CI_START="-0.4266207466878644" LOG_EFFECT_SIZE="-0.21955695283677157" ORDER="30760" O_E="0.0" SE="0.24326059498088445" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" VAR="0.05917571707045391" WEIGHT="36.55931380482279"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8301365397294154" CI_START="0.005540226601603401" DF="0" EFFECT_SIZE="0.10069444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-004.04.08" LOG_CI_END="0.26248349204680727" LOG_CI_START="-2.2564724717673568" LOG_EFFECT_SIZE="-0.9969944898602747" NO="8" P_CHI2="1.0" P_Z="0.12078319944887429" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="57" WEIGHT="100.0" Z="1.5514946040995456">
<NAME>Speech disorder</NAME>
<DICH_DATA CI_END="1.8301365397294154" CI_START="0.005540226601603401" EFFECT_SIZE="0.10069444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.26248349204680727" LOG_CI_START="-2.2564724717673568" LOG_EFFECT_SIZE="-0.9969944898602747" ORDER="30761" O_E="0.0" SE="1.4796472021775589" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" VAR="2.1893558429118776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0369591153694673" CI_END="0.8972103471195758" CI_START="0.28795287799461977" DF="1" EFFECT_SIZE="0.5082856496298451" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" I2="3.5641825045627558" ID="CMP-004.04.09" LOG_CI_END="-0.04710572653911068" LOG_CI_START="-0.5406785764814055" LOG_EFFECT_SIZE="-0.2938921515102581" NO="9" P_CHI2="0.30853008486890876" P_Z="0.019591793517437832" STUDIES="2" TAU2="0.0" TOTAL_1="189" TOTAL_2="182" WEIGHT="100.0" Z="2.3340750301254976">
<NAME>Weight gain</NAME>
<DICH_DATA CI_END="1.4155282586165132" CI_START="0.309013799475547" EFFECT_SIZE="0.6613756613756614" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.1509185437390707" LOG_CI_START="-0.5100221260694462" LOG_EFFECT_SIZE="-0.1795517911651877" ORDER="30762" O_E="0.0" SE="0.3882398211546038" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.15073015873015874" WEIGHT="48.87983706720978"/>
<DICH_DATA CI_END="0.8693280383261791" CI_START="0.15066240925752755" EFFECT_SIZE="0.3619047619047619" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.06081631290447926" LOG_CI_START="-0.8219950920017766" LOG_EFFECT_SIZE="-0.44140570245312793" ORDER="30763" O_E="0.0" SE="0.44712018273747683" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" VAR="0.19991645781119466" WEIGHT="51.12016293279022"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3860628677999397" CI_START="0.09249160089937422" DF="0" EFFECT_SIZE="0.1889644746787604" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="42" I2="0.0" ID="CMP-004.04.21" LOG_CI_END="-0.4133419675681046" LOG_CI_START="-1.0338977034628218" LOG_EFFECT_SIZE="-0.7236198355154634" NO="21" P_CHI2="1.0" P_Z="4.854867950332521E-6" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0" Z="4.570963522121814">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="0.38606286779993965" CI_START="0.09249160089937422" EFFECT_SIZE="0.1889644746787604" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="42" LOG_CI_END="-0.41334196756810465" LOG_CI_START="-1.0338977034628218" LOG_EFFECT_SIZE="-0.7236198355154634" ORDER="30764" O_E="0.0" SE="0.36451751106499103" STUDY_ID="STD-Tohen-2000" TOTAL_1="126" TOTAL_2="125" VAR="0.13287301587301587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="22" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Indigestion</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="23" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Insomnia</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="63.74460699118725" CI_END="-0.17013577248866324" CI_START="-0.5683161174828171" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3692259449857402" ESTIMABLE="YES" I2="95.29371951353508" I2_Q="96.30367594408682" ID="CMP-004.05" NO="5" P_CHI2="9.35918009759007E-14" P_Q="1.7811307984061386E-12" P_Z="2.781064354163162E-4" Q="54.107810076892655" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="428" TOTAL_2="425" UNITS="" WEIGHT="300.0" Z="3.634883355884596">
<NAME>Adverse events (continuous)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.636796914294585" CI_END="-1.623614412138286" CI_START="-2.648599402308495" DF="1" EFFECT_SIZE="-2.1361069072233905" ESTIMABLE="YES" I2="89.62310808359294" ID="CMP-004.05.01" NO="1" P_CHI2="0.0019071960258388865" P_Z="3.1024582934784363E-16" STUDIES="2" TAU2="0.0" TOTAL_1="186" TOTAL_2="180" WEIGHT="100.0" Z="8.169275931718468">
<NAME>Weight gain</NAME>
<CONT_DATA CI_END="-0.9451813040176286" CI_START="-2.194818695982372" EFFECT_SIZE="-1.5700000000000003" ESTIMABLE="YES" MEAN_1="0.92" MEAN_2="2.49" ORDER="30765" SD_1="2.49" SD_2="2.51" SE="0.31879090682832023" STUDY_ID="STD-Tohen-2000" TOTAL_1="123" TOTAL_2="123" WEIGHT="67.27705738593123"/>
<CONT_DATA CI_END="-2.4040962908609034" CI_START="-4.195903709139098" EFFECT_SIZE="-3.3000000000000007" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="8.8" ORDER="30766" SD_1="2.49" SD_2="2.51" SE="0.45710212851147863" STUDY_ID="STD-Zajecka-2002" TOTAL_1="63" TOTAL_2="57" WEIGHT="32.72294261406878"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2760767240898174" CI_START="-0.6160767240898174" DF="0" EFFECT_SIZE="-0.17" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" NO="2" P_CHI2="1.0" P_Z="0.45509798672883595" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.0" Z="0.7469429794878083">
<NAME>Abnormal involuntary movement scale</NAME>
<CONT_DATA CI_END="0.2760767240898174" CI_START="-0.6160767240898175" EFFECT_SIZE="-0.17" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="-0.1" ORDER="30767" SD_1="2.08" SD_2="1.43" SE="0.22759434745149082" STUDY_ID="STD-Tohen-2000" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.22696153279698014" CI_START="-0.2669615327969802" DF="0" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.03" NO="3" P_CHI2="1.0" P_Z="0.8738845504921537" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="122" WEIGHT="100.0" Z="0.15872625686618855">
<NAME>Akathisia</NAME>
<CONT_DATA CI_END="0.22696153279698014" CI_START="-0.2669615327969802" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.26" MEAN_2="-0.24" ORDER="30768" SD_1="1.04" SD_2="0.91" SE="0.12600309737575854" STUDY_ID="STD-Tohen-2000" TOTAL_1="119" TOTAL_2="122" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07644064725548419" CI_END="4.790289081589219" CI_START="0.827795712149469" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8090423968693443" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="0.7821801809501528" P_Q="1.0" P_Z="0.005454877846662649" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="180" UNITS="" WEIGHT="100.0" Z="2.7788674531906734">
<NAME>Mean change on MRS</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.399551170741141" CI_START="0.6004488292588595" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="-10.4" MEAN_2="-13.4" ORDER="30769" SD_1="10.4" SD_2="8.8" SE="1.2242832978914377" STUDY_ID="STD-Tohen-2000" TOTAL_1="123" TOTAL_2="125" WEIGHT="68.17373281155744"/>
<CONT_DATA CI_END="5.91192878443958" CI_START="-1.1119287844395824" EFFECT_SIZE="2.3999999999999986" ESTIMABLE="YES" MEAN_1="-14.8" MEAN_2="-17.2" ORDER="30770" SD_1="10.4" SD_2="8.8" SE="1.7918333255821164" STUDY_ID="STD-Zajecka-2002" TOTAL_1="60" TOTAL_2="55" WEIGHT="31.82626718844256"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Valproate v. haloperidol</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.35171500392524" CI_START="0.4567138316751673" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="100.0" ID="CMP-005.01" LOG_CI_END="0.13088513445339425" LOG_CI_START="-0.34035583549342024" LOG_EFFECT_SIZE="-0.104735350520013" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.38363350401907126" Q="1.0054007167309634E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.8712210016483587">
<NAME>Clinical response - categorical outcomes</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.35171500392524" CI_START="0.4567138316751673" DF="0" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.13088513445339425" LOG_CI_START="-0.34035583549342024" LOG_EFFECT_SIZE="-0.104735350520013" NO="1" P_CHI2="1.0" P_Z="0.38363350401907126" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.8712210016483587">
<NAME>Failure to respond clinically &lt;50% improvement on YMRS.</NAME>
<DICH_DATA CI_END="1.35171500392524" CI_START="0.4567138316751673" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.13088513445339425" LOG_CI_START="-0.34035583549342024" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="30771" O_E="0.0" SE="0.27680927842718106" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="0.07662337662337664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.26329884233526" CI_START="-2.6632988423352613" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.299999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.27809239065342684" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.084614626901596">
<NAME>Duration of hospital admission</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.26329884233526" CI_START="-2.6632988423352613" EFFECT_SIZE="3.299999999999999" ESTIMABLE="YES" MEAN_1="18.2" MEAN_2="14.9" ORDER="30772" SD_1="9.0" SD_2="9.0" SE="3.04255531702266" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal from trial</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal from trial due to failure to respond</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal from trial due to adverse events</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.6586029490095315" CI_END="0.6006958519737923" CI_START="0.106609664657829" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2530612244897959" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" I2="11.638967337773925" I2_Q="8.613704608614091" ID="CMP-005.04" LOG_CI_END="-0.22134536700572063" LOG_CI_START="-0.9722034227268366" LOG_EFFECT_SIZE="-0.5967743948662786" METHOD="MH" NO="4" P_CHI2="0.34086781119527076" P_Q="0.3611055132287746" P_Z="0.0018362143371550286" Q="5.471279887849903" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="126" TOTAL_2="90" WEIGHT="600.0" Z="3.1155191368634005">
<NAME>Adverse events (dichotomous)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6885611843874702" CI_START="0.0026579953933993108" DF="0" EFFECT_SIZE="0.0427807486631016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-0.16205746301599216" LOG_CI_START="-2.575445776073119" LOG_EFFECT_SIZE="-1.3687516195445555" NO="1" P_CHI2="1.0" P_Z="0.026203354139905582" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0" Z="2.2231846102626736">
<NAME>Extra-pyramidal side effects</NAME>
<DICH_DATA CI_END="0.6885611843874705" CI_START="0.0026579953933993108" EFFECT_SIZE="0.0427807486631016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.16205746301599194" LOG_CI_START="-2.575445776073119" LOG_EFFECT_SIZE="-1.3687516195445555" ORDER="30773" O_E="0.0" SE="1.417636241554576" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="2.009692513368984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Increased appetite</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.573857953557396" CI_START="0.010543776645305338" DF="0" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.04.06" LOG_CI_END="0.7461558967826932" LOG_CI_START="-1.9770038025545809" LOG_EFFECT_SIZE="-0.6154239528859439" NO="6" P_CHI2="1.0" P_Z="0.37567728595746785" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0" Z="0.8858891259100786">
<NAME>Headache</NAME>
<DICH_DATA CI_END="5.573857953557396" CI_START="0.010543776645305338" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7461558967826932" LOG_CI_START="-1.9770038025545809" LOG_EFFECT_SIZE="-0.6154239528859439" ORDER="30774" O_E="0.0" SE="1.599597487248627" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="2.558712121212121" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4419047658688178" CI_START="0.022115021641409792" DF="0" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-005.04.07" LOG_CI_END="0.15893657728806962" LOG_CI_START="-1.6553126313004702" LOG_EFFECT_SIZE="-0.7481880270062004" NO="7" P_CHI2="1.0" P_Z="0.1059732358246773" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0" Z="1.6165602604694969">
<NAME>Sedation</NAME>
<DICH_DATA CI_END="1.4419047658688178" CI_START="0.022115021641409792" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.15893657728806962" LOG_CI_START="-1.6553126313004702" LOG_EFFECT_SIZE="-0.7481880270062004" ORDER="30775" O_E="0.0" SE="1.0656989658033293" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="1.1357142857142857" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.072843433278012" CI_START="0.02734858865533279" DF="0" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-005.04.21" LOG_CI_END="0.3165665000527149" LOG_CI_START="-1.563065080848516" LOG_EFFECT_SIZE="-0.6232492903979004" NO="21" P_CHI2="1.0" P_Z="0.19367915657400722" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0" Z="1.299771907412125">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="2.072843433278012" CI_START="0.02734858865533279" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3165665000527149" LOG_CI_START="-1.563065080848516" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="30776" O_E="0.0" SE="1.1041048949477668" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="1.219047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.351770640659172" CI_START="0.14219961965869868" DF="0" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.04.22" LOG_CI_END="1.156905485183571" LOG_CI_START="-0.8471015652120845" LOG_EFFECT_SIZE="0.1549019599857432" NO="22" P_CHI2="1.0" P_Z="0.7618935168518528" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0" Z="0.302995204180325">
<NAME>Indigestion</NAME>
<DICH_DATA CI_END="14.351770640659172" CI_START="0.14219961965869868" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.156905485183571" LOG_CI_START="-0.8471015652120845" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="30777" O_E="0.0" SE="1.1771636613972951" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="1.3857142857142857" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="50.16472158201657" CI_START="0.09489398980774802" DF="0" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.04.23" LOG_CI_END="1.700398406222018" LOG_CI_START="-1.022761293115256" LOG_EFFECT_SIZE="0.33881855655338095" NO="23" P_CHI2="1.0" P_Z="0.6257469136421184" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="100.0" Z="0.4877217948694578">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="50.16472158201657" CI_START="0.09489398980774802" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.700398406222018" LOG_CI_START="-1.022761293115256" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="30778" O_E="0.0" SE="1.599597487248627" STUDY_ID="STD-McElroy-1996" TOTAL_1="21" TOTAL_2="15" VAR="2.558712121212121" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events (continuous)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Weight gain</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Abnormal involuntary movement scale</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Akathisia</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>